Diabetic Ketoacidosis

On this page

Quick Reference

RxDrug of choiceIV regular insulin: 0.1 U/kg bolus (optional) then 0.1 U/kg/h continuous infusion

AltAlternativesSubcutaneous rapid-acting insulin analogues (lispro, aspart) every 1-2 hours for mild DKA in monitored settings

⊘AvoidSGLT2 inhibitors during acute illness; routine bicarbonate; non-dihydropyridine CCBs

DxTest of choiceSerum β-hydroxybutyrate (≥3.0 mmol/L in children, ≥3.8 mmol/L in adults)

ScKey scoreDKA severity classification: mild (pH 7.25-7.30, bicarbonate 15-18), moderate (pH 7.0-7.24, bicarbonate 10-14), severe (pH <7.0, bicarbonate <10)

→When to referICU for severe DKA (pH <7.0, bicarbonate <5, altered mental status, hypotension); endocrinology for recurrent DKA, atypical presentation, or technology evaluation

DKA is a preventable metabolic crisis; early recognition, protocolized management with balanced fluids and low-dose insulin, and long-term use of CGM/AID reduce morbidity and mortality to <1%.

Diabetic ketoacidosis (DKA) is an acute metabolic emergency defined by the triad of hyperglycemia, ketosis, and metabolic acidosis. It is the leading cause of hospitalization and death in children and young adults with type 1 diabetes, with a 30-day readmission rate of 19.4% and significant mortality when complicated by acute kidney injury. Prompt recognition and protocolized management, fluid resuscitation, insulin therapy, and electrolyte correction, reduce in-hospital mortality to <1%. However, recurrence is common, and prevention through technology (CGM, automated insulin delivery) and structured education is essential. This overview provides a stepwise approach to diagnosis, acute management, and long-term prevention.

Overview and Recommendations

Background

•Diabetic ketoacidosis (DKA) is an acute metabolic emergency defined by the triad of hyperglycemia (>250 mg/dL), ketosis (serum β-hydroxybutyrate ≥3 mmol/L), and metabolic acidosis (pH <7.3, bicarbonate <15 mEq/L, anion gap >12). Absolute or relative insulin deficiency coupled with counterregulatory hormone excess (glucagon, catecholamines, cortisol) drives unchecked lipolysis, hepatic ketogenesis, and gluconeogenesis.
•DKA is the leading cause of hospitalization and death in children and young adults with type 1 diabetes. The 30-day all-cause readmission rate is 19.4%, and acute kidney injury complicates 37.8% of DKA hospitalizations, increasing mortality from 0.9% to 4.1%. In children, 41.9% of new-onset type 1 diabetes presents with DKA globally, with rates ranging from 15.6% in Sweden to 78.5% in Thailand.
•The syndrome encompasses multiple variants: classic autoimmune type 1 diabetes DKA, ketosis-prone type 2 diabetes (KPD) with preserved β-cell function and negative autoantibodies, euglycemic DKA (glucose <250 mg/dL) most often associated with use, immune checkpoint inhibitor-associated DKA (69.7% present with DKA), and fulminant type 1 diabetes with near-normal HbA1c. The Aβ classification system stratifies KPD by autoantibody status and β-cell reserve, predicting long-term insulin dependence.
•Incidence in established type 1 diabetes is 1.4-4.8 per 100 patient-years, with higher rates in adolescents, females, and those with lower socioeconomic status. The strongest iatrogenic risks come from (RR 2.23-2.59) and immune checkpoint inhibitors. Eating disorders confer a 3.3-fold increased DKA risk (HR 3.30) and a 6-fold increase in mortality. A prior DKA event is the single most actionable risk factor.
•The pathophysiology centers on a high glucagon-to-insulin ratio that activates hormone-sensitive lipase, releasing free fatty acids that the liver converts to ketone bodies (β-hydroxybutyrate, acetoacetate). (FABP4) is a necessary regulator of ketogenesis in insulin-deficient states; FABP4 levels correlate inversely with pH and bicarbonate. Hyperglycemia results from increased hepatic glucose output and reduced peripheral glucose utilization.

Evaluation

•Suspect DKA in any patient with polyuria, polydipsia, weight loss, nausea, vomiting, diffuse abdominal pain, Kussmaul respirations, or altered mental status. The classic triad of symptoms evolves over hours to days; abdominal pain can mimic an acute surgical abdomen.
•Ask about missed insulin doses, infection, use of or immune checkpoint inhibitors, pregnancy, recent surgery, alcohol use, or a history of eating disorders. In established type 1 diabetes, a prior DKA event is the strongest predictor.
•Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), fruity acetone odor on breath, deep rapid breathing (Kussmaul respirations), and abdominal tenderness without peritonitis. Assess mental status using the ; lethargy, confusion, or coma correlate with severity of acidosis and hyperosmolality.
•In children, monitor for cerebral edema: headache, vomiting, bradycardia, hypertension, papilledema, or declining GCS. Cerebral edema typically develops 4-12 hours after treatment initiation but can be present at diagnosis.
•Order a venous blood gas (acceptable in place of arterial; venous pH is 0.02-0.05 units lower), serum glucose, electrolytes (including bicarbonate), BUN, creatinine, calculated anion gap, and serum osmolality. Point-of-care β-hydroxybutyrate is the preferred ketone measure; urine ketone dipsticks detect acetoacetate but not β-hydroxybutyrate and may underestimate ketosis.
•Diagnostic criteria: hyperglycemia >250 mg/dL (13.9 mmol/L); venous pH <7.3; serum bicarbonate <18 mmol/L; anion gap >10-12 mEq/L; serum β-hydroxybutyrate ≥3.0 mmol/L (children) or ≥3.8 mmol/L (adults). For euglycemic DKA, glucose may be <250 mg/dL, check ketones in any patient with unexplained high anion gap acidosis, especially those on SGLT2 inhibitors.
•Classify severity: mild (pH 7.25-7.30, bicarbonate 15-18 mmol/L), moderate (pH 7.0-7.24, bicarbonate 10-14 mmol/L), severe (pH <7.0, bicarbonate <10 mmol/L). Severe DKA, altered mental status, or hypotension warrants ICU admission.
•Identify the precipitating cause: history of missed insulin, infection, myocardial infarction, stroke, pancreatitis, alcohol, SGLT2i use, immune checkpoint inhibitor therapy, or pregnancy. Order chest radiography, ECG, lipase, cardiac biomarkers, and cultures as indicated.
•In new-onset adults, after stabilization check HbA1c, C-peptide, and islet autoantibodies (GAD65, IA-2, ZnT8) to classify diabetes type. Ketosis-prone type 2 diabetes is suggested by high BMI, , negative antibodies, and preserved C-peptide (>0.3 nmol/L).
•Consider mixed DKA- (HHS) when effective osmolality >320 mOsm/kg with DKA criteria; this combination carries an adjusted odds ratio of 2.7 for in-hospital mortality. Differential diagnoses include , uremia, and toxic ingestions, exclude by history, lactate level, and renal function.

Management

•Initiate fluid resuscitation first: administer 15-20 mL/kg of isotonic crystalloid over the first hour (typically 1 L in adults). The 2024 consensus recommends balanced crystalloids (e.g., lactated Ringer's) over 0.9% saline to reduce hyperchloremic acidosis. After the initial bolus, continue at 4-14 mL/kg/h based on corrected serum sodium and volume status, aiming to replace the deficit (6-8 L in adults) over 24-48 hours.
•Start intravenous regular insulin with a 0.1 U/kg bolus (optional) followed by 0.1 U/kg/h continuous infusion. A bolus is unnecessary if the infusion is started immediately. For mild DKA, subcutaneous rapid-acting insulin analogues (lispro, aspart) every 1-2 hours are a safe alternative in monitored settings.
•Replace potassium when serum K+ <5.3 mEq/L, aiming for 4-5 mEq/L. Add 20-30 mEq/L to each liter of IV fluid. If K+ <3.3 mEq/L, hold insulin and give 40 mEq/h until >3.3 mEq/L to avoid fatal arrhythmias. Severe hypokalemia (≤2.5 mEq/L) is associated with a 4.9-fold increase in mortality.
•Do NOT administer bicarbonate routinely. Use only if pH <6.9: 100 mmol NaHCO₃ in 400 mL sterile water over 2 hours for pH 6.9-7.0; 200 mmol over 2 hours for pH <6.9. Bicarbonate does not improve outcomes and may worsen hypokalemia and intracellular acidosis.
•Monitor glucose hourly until stable, then every 2 hours. Check electrolytes (Na, K, Cl, bicarbonate) every 2-4 hours. Measure β-hydroxybutyrate every 2-4 hours; resolution is defined as <0.3 mmol/L. Check venous pH every 2-4 hours until >7.3.
•When glucose falls to 200-250 mg/dL, reduce insulin infusion to 0.02-0.05 U/kg/h and add dextrose 5-10% to maintain glucose 150-200 mg/dL until ketoacidosis resolves. Do not stop insulin when glucose falls, add dextrose instead.
•DKA resolves when glucose <200 mg/dL, pH >7.3, bicarbonate >15 mEq/L, and anion gap normal. Transition to subcutaneous insulin when the patient is eating and the gap is closed. Overlap IV and SC insulin by 1-2 hours to prevent rebound hyperglycemia.
•Avoid: routine bicarbonate, stopping insulin when glucose falls, rapid correction of hyperosmolality (risk of ), and delaying insulin for hypokalemia (correct K+ first). Do not use non-dihydropyridine CCBs (diltiazem, verapamil) as they exacerbate metabolic acidosis.
•For SGLT2 inhibitor-associated DKA, hold the drug during acute illness and restart only after metabolic stability. These patients often present with euglycemic DKA, insulin and fluid therapy are the same; monitor ketones closely.
•Refer to ICU for severe DKA (pH <7.0, bicarbonate <5 mEq/L, altered mental status, hypotension, or combined DKA-HHS). Refer to endocrinology for recurrent DKA, atypical presentation, or consideration of advanced diabetes technology (CGM, automated insulin delivery).
•Discharge criteria: resolution of ketoacidosis, stable glucose on subcutaneous regimen, education on sick-day rules (including SGLT2i hold during illness), and follow-up with endocrinology within 2 weeks. Screen for psychosocial barriers (eating disorders, depression) and refer for diabetes self-management education.
•Long-term prevention: optimize insulin delivery with continuous glucose monitoring (CGM; reduces DKA risk by 60%) and automated insulin delivery (AID). Consider low-dose 2.5 mg as adjunct in selected type 1 diabetes patients with ketone monitoring. Screen first-degree relatives with islet autoantibody testing to identify presymptomatic type 1 diabetes and reduce DKA at onset to <5%.

Board Review — High Yield

•Euglycemic DKA, glucose <250 mg/dL, associated with SGLT2 inhibitor use; check serum ketones in any patient with high anion gap acidosis even if glucose is normal.
•Cerebral edema, most feared complication in children, occurs 4-12 hours after treatment initiation; avoid rapid osmolality correction; treat with mannitol 0.25-1 g/kg IV.
•Anion gap metabolic acidosis, closure of the gap indicates resolution; persistent gap after ketones normalize suggests concurrent lactic acidosis or other unmeasured anions.
•Ketosis-prone type 2 diabetes (KPD), autoantibody-negative, preserved C-peptide; often presents with DKA but may achieve insulin independence; look for acanthosis nigricans and obesity.
•Low-dose insulin therapy, 0.1 U/kg/h IV is standard; reduces hypoglycemia and hypokalemia risk compared to high-dose regimens (established by Fisher and Kitabchi 1977).
•Potassium replacement, hold insulin if K+ <3.3 mEq/L; severe hypokalemia (≤2.5 mEq/L) increases mortality 4.9-fold.
•Balanced crystalloids, preferred over 0.9% saline to reduce hyperchloremic acidosis; Cochrane meta-analysis shows lower mortality in critically ill adults.
•Automated insulin delivery (AID), reduces HbA1c by 0.8-1.5% and DKA risk by 60%; standard of care for type 1 diabetes in many guidelines.
•SGLT2 inhibitor DKA risk, dose-dependent; empagliflozin 2.5 mg has DKA rate comparable to placebo (0.8% vs 1.2%), while 10-25 mg increases risk to 3-4%.
•Screening for presymptomatic T1D, islet autoantibody screening reduces DKA at onset to 2.5% vs 40% in unscreened; cost-effective if DKA reduction ≥20%.

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

▸DKA is defined by the triad of hyperglycemia, ketosis, and metabolic acidosis due to insulin deficiency and counterregulatory hormone excess.
▸Several variants exist, ketosis-prone type 2 diabetes, SGLT2i-associated euglycemic DKA, checkpoint inhibitor-associated DKA, and fulminant T1DM, each requiring distinct diagnostic and management approaches.
▸The Aβ classification system (A+β-, A-β+, etc.) accurately predicts long-term insulin dependence in ketosis-prone diabetes and is the most validated scheme [8,13].

HY High Yield: Euglycemic DKA (glucose <250 mg/dL) is a high-yield exam pearl: always suspect with SGLT2 inhibitor use, especially in type 1 diabetes off-label [2,9].

Diabetic ketoacidosis (DKA) is an acute metabolic emergency defined by the triad of hyperglycemia, ketosis, and metabolic acidosis, driven by absolute or relative insulin deficiency and counterregulatory hormone excess.

Synonyms and Abbreviations

DKA is the universal abbreviation. Historical terms include "ketotic state" and "diabetic coma," though coma is now rare. “Euglycemic DKA” describes DKA with plasma glucose <250 mg/dL, most often associated with SGLT2 inhibitor therapy ^[2]^A1a^[9]^B2b. “Fulminant type 1 diabetes” (FT1DM) is a rapid-onset variant with near-normal HbA1c and extremely low C-peptide ^[18]^C4. “Ketosis-prone diabetes” (KPD) refers to a heterogeneous syndrome in which adults present with DKA but often lack the classic type 1 phenotype ^[13]^D5.

Key Diagnostic Terms

Ketosis is defined by elevated serum ketones, with beta-hydroxybutyrate (βOHB) ≥3.0 mmol/L in children and ≥3.8 mmol/L in adults, a threshold that corresponds to a bicarbonate level of 18 mEq/L ^[10]^C4. Metabolic acidosis in DKA is characterized by an arterial pH <7.30, serum bicarbonate <15 mEq/L, and a calculated anion gap >12 mEq/L. These terms anchor every diagnostic and severity classification used in later sections.

Classification of DKA Variants

The syndrome encompasses multiple subtypes with distinct etiologies and clinical trajectories. The table below summarizes the major variants that a clinician must recognize.

Name	Key Feature	Associated Marker / Subtype
Classic T1D DKA	Autoimmune β-cell destruction	Positive islet autoantibodies (GADA, IA-2A, ZnT8A); low C-peptide ^[12]^A1c
Ketosis-prone T2D (KPD)	Preserved β-cell function, antibody-negative	Obesity, , C-peptide >0.3 nmol/L; 35% of new-onset DKA in adults ^[5]^B2b^[14]^B2a
SGLT2i-associated DKA	Euglycemic (glucose <250 mg/dL)	Off-label use in T1D; risk highest in females aged 25-44 years (19.7 per 100 person-years) ^[9]^B2b
Checkpoint inhibitor-associated DKA (CIADM)	Rapid onset after anti-PD-1/PD-L1 therapy	69.7% present with DKA; autoantibodies positive in 40.4% ^[1]^B2a
Fulminant T1DM	Near-normal HbA1c, very low C-peptide	Rapid destruction of β-cells; may follow drug hypersensitivity ^[18]^C4

The Aβ classification system stratifies KPD into four subgroups based on the presence (A+) or absence (A-) of islet autoantibodies and the presence (β+) or absence (β-) of β-cell functional reserve (peak C-peptide ≥1.5 ng/mL). This scheme has the highest accuracy (sensitivity 99.4%, specificity 95.9%) for predicting long-term insulin dependence ^[8]^B2b^[13]^D5.

Clinical Significance

DKA remains the leading cause of hospitalization and death in children and young adults with type 1 diabetes. The 30-day all-cause readmission rate is 19.4%, and acute kidney injury complicates 37.8% of DKA hospitalizations, with mortality rising from 0.9% to 4.1% when AKI occurs ^[6]^B2c^[16]^B2b.

The pathophysiology underlying these presentations, the dual hormonal derangement of insulin deficiency and glucagon excess, is detailed in the following section.

Pearl: The diagnosis of DKA requires a serum βOHB ≥3.0 mmol/L in children or ≥3.8 mmol/L in adults (or pH <7.30 with bicarbonate <15 mEq/L) in the presence of hyperglycemia; euglycemic DKA (glucose <250 mg/dL) occurs with SGLT2 inhibitor use and must not be overlooked ^[2]^A1a^[9]^B2b^[10]^C4.

Axis Physiology, Pathophysiology and Biochemical Signature

▸DKA results from absolute or relative insulin deficiency with counterregulatory hormone excess, leading to unrestrained lipolysis, hepatic ketogenesis, and hyperglycemia.
▸Insulin signaling to glucose transport remains intact, but glycogen synthase activation is impaired, reducing glucose oxidation.
▸FABP4 is a necessary regulator of ketogenesis; SGLT2 inhibitors double DKA risk via enhanced ketogenesis at lower glucose levels.

HY High Yield: The nitroprusside ketone test detects acetoacetate but not β-hydroxybutyrate; during treatment, β-hydroxybutyrate converts to acetoacetate, causing a paradoxical rise in measured ketones even as acidosis resolves.

Having defined DKA as a hyperglycemic crisis characterized by the triad of hyperglycemia, ketosis, and metabolic acidosis, the underlying pathophysiology centers on an absolute or relative insulin deficiency coupled with counterregulatory hormone excess. In the normal state, insulin suppresses lipolysis, promotes glucose uptake in insulin-sensitive tissues, and inhibits hepatic gluconeogenesis and ketogenesis. Glucagon, catecholamines, cortisol, and growth hormone oppose these actions. In DKA, insulin deficiency removes the brake on lipolysis, releasing free fatty acids (FFAs) from adipose tissue. The liver takes up these FFAs and, under the influence of elevated glucagon (high glucagon-to-insulin ratio), shifts toward β-oxidation and ketone body production (acetoacetate, β-hydroxybutyrate, and acetone). Hyperglycemia results from increased hepatic gluconeogenesis and glycogenolysis combined with reduced peripheral glucose utilization. Insulin signaling to glucose transport and protein synthesis remains intact during early DKA, but insulin-stimulated dephosphorylation of glycogen synthase is impaired by approximately 30%, reducing glucose oxidation ^[19]^A1b. The ketone body 3-hydroxybutyrate (3-OHB) normally suppresses lipolysis via feedback inhibition; this pathway remains intact in type 1 diabetes, indicating that derailment of 3-OHB receptor signaling is not a primary driver of DKA ^[23]^A1b. Fatty acid-binding protein 4 (FABP4) has emerged as a necessary regulator of ketogenesis in insulin-deficient states; FABP4 levels are elevated in children presenting with DKA and correlate inversely with pH and bicarbonate, and Fabp4-knockout mice are protected from ketoacidosis despite severe hypoinsulinemia ^[43]^B2b.

Biochemical Signature

The laboratory hallmark of DKA is an anion gap metabolic acidosis (anion gap > 12 mEq/L) with elevated serum ketones. β-Hydroxybutyrate is the predominant ketone body, typically exceeding 3 mmol/L. The nitroprusside-based urine or serum ketone test detects acetoacetate but not β-hydroxybutyrate, potentially underestimating ketosis severity, especially during treatment when β-hydroxybutyrate is converted to acetoacetate. Hyperglycemia is usually > 250 mg/dL (13.9 mmol/L), though euglycemic DKA (glucose < 200 mg/dL) occurs, particularly with SGLT2 inhibitor use. Serum osmolality is elevated (typically 300-320 mOsm/kg), driven by hyperglycemia; copeptin, a surrogate for arginine vasopressin, is markedly elevated at presentation (mean 95 pmol/L) and declines with a half-life of 7.1 hours during rehydration ^[29]^B2b.

Special Pathophysiologic Mechanisms

SGLT2 inhibitor-associated DKA occurs in the setting of lower glucose levels because these drugs increase urinary glucose excretion, reduce insulin requirements, and shift metabolism toward fat oxidation and ketogenesis. The risk is approximately doubled (RR 2.19, 95%) compared with GLP-1 receptor agonists ^[48]^B2a. Glucagon receptor antagonism can mitigate this risk by suppressing ketogenesis ^[20]^A1b. Immune checkpoint inhibitor (ICI)-induced DKA results from autoimmune destruction of pancreatic β-cells, often presenting with diabetic ketoacidosis (71% of cases) and positive islet autoantibodies (53%), particularly glutamic acid decarboxylase antibodies ^[22]^C4. Ketosis-prone diabetes (KPD) encompasses syndromes of severe β-cell dysfunction without autoimmunity; the A-β- subtype (absent autoantibodies, absent β-cell functional reserve) may involve low-frequency variants in HNF1A, PDX1, or PAX4 genes ^[35]^B2b. Ectopic ACTH secretion (e.g., from pheochromocytoma) can cause DKA through glucocorticoid-driven positive-feedback loops that amplify ACTH and catecholamine production ^[27]^C4.

Parameter	Normal State	DKA State
Insulin	Present	Absent or severely deficient
Glucagon/insulin ratio	Low	High
Lipolysis	Suppressed	Activated
Hepatic ketogenesis	Minimal	Marked
Blood glucose	< 100 mg/dL	> 250 mg/dL (often)
Serum β-hydroxybutyrate	< 0.6 mmol/L	> 3 mmol/L
Anion gap	8-12 mEq/L	> 12 mEq/L
Arterial pH	7.35-7.45	< 7.30

Pearl: The anion gap in DKA is driven by ketoanions (β-hydroxybutyrate and acetoacetate); as treatment resolves ketosis, the gap closes, persistent gap after normalization of ketones should prompt a search for concurrent or other unmeasured anions.

Epidemiology, Etiology and Risk Factors

▸DKA incidence ranges from 1.4 to 4.8 per 100 patient-years in established T1D, with a global prevalence of 41.9% at T1D diagnosis in children.
▸Key modifiable risk factors include SGLT2 inhibitor use (RR 2.23), immune checkpoint inhibitors (69.7% present with DKA), eating disorders (HR 3.30), and antipsychotic exposure (OR 2.60).
▸Participation in preclinical monitoring programs reduces DKA at diagnosis to <5%, highlighting the value of early detection and education.

HY High Yield: A prior DKA episode is the strongest predictor of future DKA, always ask about it and use it as a trigger for preventive counseling [70].

From the biochemical cascade of insulin deficiency and counterregulatory hormone excess emerges a clinical syndrome with a substantial and growing global burden. Diabetic ketoacidosis (DKA) occurs at an incidence of 1.4 to 4.8 per 100 patient-years among individuals with established type 1 diabetes (T1D), with higher rates in adolescents and young adults ^[54]^B2b^[69]^B2b. In the T1D Exchange registry, 8% of participants reported at least one DKA episode in the prior 12 months ^[61]^C4. At diagnosis of T1D, the pooled global prevalence of DKA in children is 41.9% (95% CI 39.7-44.0), ranging from 15.6% in Sweden to 78.5% in Thailand ^[77]^B2a. An estimated 355,900 new cases of childhood T1D occurred globally in 2021, but only 56% were diagnosed, meaning many DKA events go uncounted ^[73]^B2c. The hyperosmolar hyperglycemic state (HHS), a related crisis, shows incidence rates of 16.5 per 10,000 person-years in T1D and 3.9 per 10,000 in type 2 diabetes (T2D) ^[55]^B2b.

Demographic Patterns

DKA disproportionately affects females, adolescents aged 13-25 years, and individuals from lower socioeconomic backgrounds or ethnic minority groups ^[60]^B3b^[69]^B2b^[70]^D5. In a Colorado cohort, public insurance, rural residence, and minority status were independently associated with DKA at T1D diagnosis ^[60]^B3b. The frequency of DKA at first presentation of T1D in children is inversely correlated with national gross domestic product and background T1D incidence ^[3]^B2a.

Temporal Trends

The prevalence of DKA at T1D diagnosis has been rising in many regions. In Colorado, community rates increased from 44% to 55% over 16 years ^[60]^B3b. The Finnish FinnDiane study reported a modest annual increase of 2.4% in DKA hospitalizations among adults with longstanding T1D ^[54]^B2b. During the pandemic, the incidence of T1D in Finnish children rose by 16% (IRR 1.16, 95%), and those diagnosed had more severe DKA ^[36]^B2b.

Risk Factors

Multiple modifiable and non-modifiable factors amplify DKA risk. The strongest iatrogenic risks come from sodium-glucose cotransporter 2 inhibitors (SGLT2i) and immune checkpoint inhibitors (ICIs). SGLT2i increase DKA risk approximately 2- to 3-fold (RR 2.23, 95% ^[51]^A1a; IRR 2.59, 95% CI 1.57-4.27 ^[2]^A1a), with higher absolute risk in patients with dementia (IRD 5.9 per 1000 person-years vs 1.1 in those without) ^[57]^B2b. ICI-associated autoimmune diabetes presents with DKA in 69.7% of cases, often within 12 weeks of therapy initiation ^[1]^B2a. Eating disorders confer a 3.3-fold increased DKA risk (HR 3.30, 95% CI 2.58-4.23) and a nearly 6-fold increase in mortality ^[65]^B2b. Antipsychotic exposure is associated with an OR of 2.60 (95% CI 1.06-6.38) for DKA in ^[66]^B3b. Pregnancy, especially in T1D with suboptimal glycemic control (median first-trimester HbA1c 9.0%), carries a fetal loss rate of 17.2% ^[58]^B3b. Conversely, participation in preclinical monitoring programs reduces DKA at diagnosis to <5% ^[60]^B3b^[76]^B2b.

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Immune checkpoint inhibitor therapy	69.7% present with DKA ^[1]^B2a	2a (systematic review)
Eating disorder (T1D)	HR 3.30 (95% CI 2.58-4.23) ^[65]^B2b	2b (population-based cohort)
Antipsychotic exposure	OR 2.60 (95% CI 1.06-6.38) ^[66]^B3b	3b (nested case-control)
High HbA1c (≥9.0%)	Rate 15.83/100 pt-yrs vs lower ^[69]^B2b	2b (registry)
Previous DKA	Strong predictor (not quantified) ^[70]^D5	5 (expert review)

Special Considerations

Infections, particularly COVID-19, can precipitate DKA through stress hyperglycemia and possible direct β-cell injury ^[63]^D5^[71]^D5^[75]^D5. No evidence links SARS-CoV-2 vaccination to increased DKA risk. Perioperative states, including bariatric surgery, require careful insulin to prevent DKA in T1D ^[67]^A1c.

Pearl: The single most actionable risk factor for DKA in established T1D is a prior DKA event, a history of DKA should trigger intensified education, psychosocial assessment, and review of insulin adherence and sick-day rules ^[70]^D5.

Clinical Presentation

▸DKA presents with the classic triad of polyuria, polydipsia, and weight loss, progressing over hours to days with nausea, vomiting, abdominal pain, Kussmaul respirations, and altered mental status.
▸Phenotypic variants include ketosis-prone type 2 diabetes (KPD) in African populations, checkpoint inhibitor-associated diabetes (ICI-DM), euglycemic DKA with SGLT2 inhibitors, and DKA in pregnancy, each with distinct management implications.
▸Red flags for severe DKA include pH <7.0, hypotension, altered mental status, and signs of cerebral edema in children; acute esophageal necrosis is a rare but life-threatening complication presenting with upper GI bleeding.

HY High Yield: In any patient with unexplained high anion gap metabolic acidosis, check serum ketones and glucose, even if glucose is normal, to avoid missing euglycemic DKA, especially in those on SGLT2 inhibitors or after bariatric surgery [92].

The clinical presentation of DKA reflects the underlying metabolic derangement: insulin deficiency drives unchecked lipolysis and ketogenesis, producing a characteristic symptom complex that evolves over hours to days. Recognizing this syndrome at the bedside allows treatment to begin before laboratory confirmation returns.

Presenting Symptoms

The classic triad, polyuria, polydipsia, and weight loss, is present in nearly all patients, often progressing over days to a week. As ketonemia worsens, nausea, vomiting, and diffuse abdominal pain emerge; the abdominal pain can mimic an acute surgical abdomen, leading to diagnostic delay ^[31]^A1c. Kussmaul respirations (deep, rapid breathing) represent a compensatory for the metabolic acidosis, and a fruity acetone odor on the breath signals elevated ketone levels. In children, symptoms progress more rapidly, and DKA is the presenting manifestation of type 1 diabetes in 12.8% to 80% of cases depending on geographic region ^[3]^B2a.

Neurological Examination Findings

Altered mental status ranges from lethargy and confusion to frank coma, correlating with the degree of acidosis and hyperosmolality. In children, cerebral edema is the most feared neurological complication; it typically develops 4-12 hours after treatment initiation but can be present at diagnosis. Signs include headache, vomiting, bradycardia, , and papilledema. A prospective pediatric cohort found that DKA at type 1 diabetes diagnosis results in morphologic brain changes, increased white matter volume and higher mean diffusivity in frontal, temporal, and parietal regions, that are associated with poorer delayed memory recall and sustained attention at 6 months ^[79]^B2b. Mental state scores are lower at baseline and at 5 days post-diagnosis ^[79]^B2b. In adults, obtundation is more common with severe acidosis (pH <7.0) or marked hyperosmolality (>320 mOsm/kg) ^[62]^D5.

Phenotypic Variants

DKA is not a monolithic entity; several distinct phenotypes exist, each with implications for and prognosis.

Variant	Key Features	Frequency / Context
Classic type 1 diabetes DKA	Lean, autoantibody-positive, low C-peptide, long-term insulin dependence	Most common in children and young adults
Ketosis-prone type 2 diabetes (KPD)	Obese, , autoantibody-negative, preserved C-peptide; often achieves insulin independence	Up to 50% of adult DKA in some African populations ^[5]^B2b^[90]^D5
Euglycemic DKA (SGLT2i-associated)	Glucose <250 mg/dL (13.9 mmol/L) with high anion gap metabolic acidosis and ketonemia; often perioperative or during illness	Increasingly recognized with SGLT2 inhibitor use ^[92]^C4
DKA in pregnancy	Lower glucose threshold for diagnosis; fetal demise in 17.2% of cases; associated with preeclampsia and large-for-gestational-age infants	Obstetric emergency; 82.8% have type 1 diabetes ^[58]^B3b
DKA in youth type 2 diabetes	Rising incidence during pandemic; 20% presented with DKA/HHS vs 3.5% prepandemic; higher BMI	Adolescents, often with obesity ^[87]^B3b

Red Flags

Certain findings demand immediate escalation of care:

Severe acidosis (pH <7.0) or bicarbonate <10 mEq/L, associated with higher risk of cerebral edema and cardiovascular collapse ^[31]^A1c.
Hypotension or shock, may indicate concurrent sepsis, myocardial infarction, or profound volume depletion.
Altered mental status ( <15), especially in children, warrants close neurological monitoring and consideration of cerebral edema.
Respiratory compromise, Kussmaul breathing may be absent in very young children or elderly patients; hypoventilation signals impending respiratory failure.
Overt upper bleeding, acute esophageal necrosis (AEN) occurs in DKA patients, presenting with hematemesis or melena; in-hospital mortality is 13.5% ^[95]^C4.

Atypical Presentations

Several scenarios can delay diagnosis:

Euglycemic DKA: glucose <250 mg/dL, often with SGLT2 inhibitor use, pregnancy, or after bariatric surgery ^[92]^C4.
DKA in pregnancy: lower glucose thresholds (≥200 mg/dL) and more rapid progression; fetal loss occurs in 17.2% of cases ^[58]^B3b.
DKA in type B insulin resistance: extreme insulin resistance requiring >4 units/kg/day, acanthosis nigricans, and biphasic glycemic course (hyperglycemia followed by hypoglycemia) ^[96]^C4.
DKA in antipsychotic-treated patients: olanzapine and clozapine are most commonly implicated; average glucose at presentation is 842.8 mg/dL ^[91]^C4.
DKA in pancreatic hypoplasia: low incidence of DKA due to lack of glucagon, but labile diabetes and poor weight gain ^[85]^B3b.

Pearl: In any patient with unexplained high anion gap metabolic acidosis, check serum ketones and glucose, even if glucose is normal, to avoid missing euglycemic DKA, especially in those on SGLT2 inhibitors or after bariatric surgery ^[92]^C4.

Diagnosis and Laboratory Confirmation

▸DKA is diagnosed by the triad of hyperglycemia (>250 mg/dL), metabolic acidosis (pH <7.3, bicarbonate <18 mmol/L), and ketosis (BOHB ≥3 mmol/L or moderate-to-large ketonuria) with an elevated anion gap.
▸Serum β-hydroxybutyrate is the preferred ketone measure; urine ketones may be falsely negative when BOHB is the predominant ketone.
▸C-peptide and autoantibodies are not needed for acute diagnosis but guide diabetes classification after stabilization, especially in adults with first-episode DKA.

HY High Yield: Euglycemic DKA (glucose <250 mg/dL) is increasingly seen with SGLT2 inhibitor therapy and during pregnancy. If suspicion is high, obtain serum BOHB and blood gas even if glucose is not markedly elevated [31][109].

Suspicion of DKA, raised by the classic triad of polyuria, polydipsia, and weight loss with Kussmaul breathing or altered mental status, requires immediate laboratory confirmation ^[31]^A1c. The diagnosis rests on a constellation of biochemical abnormalities, not a single test, and can be confirmed within minutes using point-of-care blood gas and ketone meters.

Gold-Standard Diagnostic Criteria

The 2024 ADA/EASD/JBDS/AACE/DTS consensus report defines DKA by four concurrent findings ^[31]^A1c^[40]^A1c:

Hyperglycemia: serum glucose >250 mg/dL (13.9 mmol/L)
Metabolic acidosis: venous pH <7.3 or serum bicarbonate <18 mmol/L
Ketosis: serum β-hydroxybutyrate (BOHB) ≥3 mmol/L or moderate-to-large ketonuria
Anion gap: >10-12 mEq/L (calculated as Na⁺ - [Cl⁻ + HCO₃⁻])

Severity is classified as mild (pH 7.25-7.30, bicarbonate 15-18 mmol/L), moderate (pH 7.0-7.25, bicarbonate 10-15 mmol/L), or severe (pH <7.0, bicarbonate <10 mmol/L) - this stratification is detailed in the next section.

Criterion	Diagnostic Threshold	Rationale
Plasma glucose	>250 mg/dL (13.9 mmol/L)	DKA is uncommon below this level; euglycemic DKA (glucose <250 mg/dL) occurs with SGLT2 inhibitor use or pregnancy ^[31]^A1c
Venous pH	<7.3	Acceptable in place of arterial pH; venous pH is 0.02-0.05 units lower ^[31]^A1c
Serum bicarbonate	<18 mmol/L	More sensitive than pH for mild acidosis ^[40]^A1c
Anion gap	>10-12 mEq/L	Elevated due to unmeasured anions (ketoacids)
β-Hydroxybutyrate	≥3.0 mmol/L (laboratory or point-of-care)	Preferred over urine ketones; acetoacetate-based urine tests may underestimate ketosis after BOHB is the predominant ketone ^[119]^D5

Laboratory Studies

Initial laboratory panel must include: venous blood gas (or arterial if venous unavailable), serum glucose, electrolytes (including bicarbonate), BUN, creatinine, calculated anion gap, and serum osmolality (measured or calculated). Serum BOHB is the ketone measure of choice; urine ketones (dipstick) are semiquantitative and can be falsely negative when BOHB is the only ketone body present ^[119]^D5.

, lipase, and cardiac biomarkers are indicated to screen for precipitating factors: infection, pancreatitis, or myocardial ischemia. HbA1c at presentation reflects the preceding 2-3 months of glycemia; a normal or mildly elevated HbA1c with severe hyperglycemia suggests a rapid onset (e.g., immune checkpoint inhibitor-associated diabetes ^[86]^C4^[112]^D5).

C-peptide and autoantibodies (GAD65, IA-2, ZnT8, insulin antibodies) are not required for acute DKA diagnosis but are essential for classifying diabetes type after stabilization. In adults with first-episode DKA, a high BMI, , and negative antibodies with preserved C-peptide (>0.3 nmol/L) suggest ketosis-prone type 2 diabetes, which may permit eventual insulin weaning ^[5]^B2b.

Imaging

No imaging is necessary for the diagnosis of DKA itself. However, chest radiography, CT chest/abdomen, or MRI brain should be obtained when a precipitating cause is suspected (e.g., pneumonia, acute pancreatitis, cerebral edema in a child with severe DKA). Thyroid function tests and cortisol levels are warranted if or adrenal insufficiency is considered ^[80]^C4^[107]^C4.

Diagnostic Algorithm

Step 1: Obtain point-of-care glucose and urine ketones or serum BOHB in any patient with suggestive symptoms. If glucose >250 mg/dL and ketones moderate/large or BOHB ≥3 mmol/L, proceed to Step 2.

Step 2: Draw venous blood gas, serum electrolytes (with bicarbonate), and calculated anion gap. If pH <7.3 and bicarbonate <18 mmol/L with anion gap >12, DKA is confirmed.

Step 3: Assess severity by pH and bicarbonate (see next section).

Step 4: Identify the precipitating cause: history of missed insulin doses, infection, myocardial infarction, stroke, pancreatitis, alcohol use, SGLT2 inhibitor use, immune checkpoint inhibitor therapy, or pregnancy. If the patient is on an SGLT2 inhibitor, check for euglycemic DKA (glucose <250 mg/dL with ketosis and acidosis).

Step 5: If the patient is not known to have diabetes, check HbA1c, C-peptide, and islet autoantibodies after initial stabilization to classify diabetes type.

Differential Diagnosis

The major alternative is hyperosmolar hyperglycemic state (HHS), which presents with extreme hyperglycemia (>600 mg/dL, often >1000 mg/dL), effective osmolality >320 mOsm/kg, and little to no ketosis or acidosis ^[55]^B2b^[62]^D5. However, mixed DKA-HHS occurs in up to 65% of HHS cases ^[110]^C4. Other causes of high-anion-gap metabolic acidosis ( , uremia, toxic ingestions) are excluded by history, lactate level, and renal function.

Pearl: In a patient with known type 1 diabetes who presents with vomiting and abdominal pain, always check a blood gas and ketones - DKA can mimic an acute surgical abdomen, and delaying insulin therapy for abdominal imaging increases the risk of deterioration ^[31]^A1c.

Severity, Staging and Risk Stratification

▸DKA severity is graded by pH, bicarbonate, and mental status; combined DKA-HHS carries a 2.7-fold higher mortality.
▸In children, a risk model using maximum glucose, initial pH, and type 2 diabetes status predicts adverse outcomes with AUC >0.94.
▸Prehospital-to-hospital lactate ratio <1.23 and rhabdomyolysis (CK >1,000 U/L) are powerful independent predictors of in-hospital mortality in adults.

HY High Yield: In children with DKA, the triad of severe acidosis, early insulin administration, and high-volume fluid resuscitation in the first 4 hours are the strongest modifiable risk factors for cerebral edema [143].

Once the diagnosis of DKA is confirmed, the next step is to stratify severity and identify patients at highest risk for adverse outcomes. Severity grading guides the intensity of monitoring and the setting of care, while risk stratification flags those who may require more aggressive intervention.

Severity Classification

DKA is graded as mild, moderate, or severe based on the degree of acidosis and mental status. The table below summarizes the standard criteria, which are used to triage patients to appropriate care settings (e.g., ward vs. intensive care unit).

Severity	pH	Serum bicarbonate (mEq/L)	Anion gap	Mental status
Mild	7.25-7.30	15-18	>10	Alert
Moderate	7.00-7.24	10-14	>12	Alert or drowsy
Severe	<7.00	<10	>12	Stupor/coma

Adapted from ADA criteria; see ^[136]^B2b and ^[139]^B2b.

Patients with combined DKA and hyperosmolar hyperglycemic state (HHS), defined by DKA criteria plus effective osmolality >320 mOsm/kg, represent a particularly high-risk group. In a large cohort, combined DKA-HHS carried an adjusted odds ratio for in-hospital mortality of 2.7 (95% CI 1.4-4.9) compared with isolated DKA or HHS ^[136]^B2b.

Risk Stratification for Adverse Outcomes

Several clinical and biochemical factors independently predict poor outcomes, including death, prolonged ICU stay, and cerebral edema.

In adults:

Hypoglycemia (<40 mg/dL [2.2 mmol/L]) during treatment was associated with a 4.8-fold increase in mortality (aOR 4.8; 95% CI 1.4-16.8) ^[136]^B2b.
Severe hypokalemia (≤2.5 mEq/L) also increased mortality (aOR 4.9; 95% CI 1.3-18.8) ^[136]^B2b.
Prehospital-to-hospital lactate ratio <1.23 was independently associated with a dramatic increase in in-hospital mortality (HR 105.21; p<0.001) in severe DKA ^[146]^B2b.
(peak CK >1,000 U/L) occurred in 1.96% of admissions and was linked to higher mortality (11.1% vs. 0.67%) and composite poor outcome (16.7% vs. 1.11%) ^[147]^B2b. Independent predictors of poor outcome included leukocytosis >9.5×10⁹/L (aOR 4.29) and troponin I >0.03 ng/mL (aOR 5.79) ^[147]^B2b.

In children: A multivariable model incorporating maximum serum glucose, initial pH, and diagnosis of type 2 diabetes had excellent discrimination for adverse outcomes (death or ICU stay >48 hours), with an AUC of 0.948 in the training dataset and 0.960 in a validation cohort ^[139]^B2b. The proportion of children with type 2 diabetes increased during the pandemic, contributing to higher adverse outcome rates ^[139]^B2b.

Cerebral edema, the leading cause of DKA-related mortality in children, is associated with more severe acidosis at presentation, higher baseline potassium and urea, early insulin administration (OR 12.7), and larger fluid volumes in the first 4 hours (OR 6.55) ^[143]^B3b.

Prognostic Biomarkers

Euthyroid sick syndrome (ESS) is present in 61.5% of children with DKA at presentation ^[94]^B3b. Severe DKA is associated with lower rates of FT4 normalization at 2 weeks (50.0% vs. 84.8%; p=0.002), underscoring that thyroid function tests during acute DKA should not be used to diagnose primary thyroid disease ^[94]^B3b.
in adults with first-episode DKA strongly predicts insulin independence at 12 months (OR 27.1) and 5 years (OR 11.5), identifying a phenotype of ketosis-prone type 2 diabetes that may eventually be weaned off insulin ^[5]^B2b.

Pearl: The combination of severe acidosis (pH <7.0), hyperosmolality (effective osmolality >320 mOsm/kg), and a falling lactate ratio (<1.23 from prehospital to hospital) identifies a patient with a mortality risk exceeding 50%, such patients warrant immediate ICU-level care and close monitoring for cerebral edema, rhabdomyolysis, and cardiac injury.

Key Risk Factors for Adverse Outcomes in DKA

Factor	Population	Effect size	Reference
Combined DKA-HHS	Adults	aOR 2.7 for mortality	^[136]^B2b
Hypoglycemia <40 mg/dL	Adults	aOR 4.8 for mortality	^[136]^B2b
Severe hypokalemia ≤2.5 mEq/L	Adults	aOR 4.9 for mortality	^[136]^B2b
Lactate ratio <1.23	Adults	HR 105 for mortality	^[146]^B2b
Rhabdomyolysis (CK >1,000 U/L)	Adults	11.1% vs 0.67% mortality	^[147]^B2b
Max glucose, low pH, type 2 diabetes	Children	AUC 0.948 for adverse outcome	^[139]^B2b
Early insulin, high fluid volume	Children	OR 12.7 and 6.55 for cerebral edema	^[143]^B3b

Acute Management and Endocrine Emergencies

▸Fluid resuscitation with balanced crystalloids (e.g., lactated Ringer's) is preferred over 0.9% saline to reduce hyperchloremic acidosis and shorten DKA resolution [15,31].
▸Insulin therapy should be started after potassium is >3.3 mEq/L; severe hypokalemia (≤2.5 mEq/L) is associated with a 4.9-fold increase in mortality [136].
▸Bicarbonate is indicated only for pH <6.9; routine use does not improve outcomes and may worsen hypokalemia [31,40].

Rx Drug of Choice: **First-line insulin regimen:** IV regular insulin 0.1 U/kg bolus (optional) then 0.1 U/kg/h continuous infusion [31,40].

! Warning: **Do not use bicarbonate unless pH <6.9.** Bicarbonate therapy does not improve outcomes and may worsen hypokalemia and intracellular acidosis [31,40].

Once the severity of DKA is classified (mild, moderate, severe) and the disposition determined, ICU for severe DKA (pH <7.0 or bicarbonate <5 mEq/L) or altered mental status, ward for mild-to-moderate, proceeds through a structured sequence of fluid resuscitation, insulin therapy, and electrolyte correction, with simultaneous identification and treatment of the precipitating cause ^[31]^A1c^[40]^A1c. The ADA/EASD/JBDS/AACE/DTS 2024 consensus report provides the framework for this stepwise approach ^[31]^A1c^[40]^A1c.

Step 1: Fluid Resuscitation

Administer 15-20 mL/kg of isotonic crystalloid over the first hour (typically 1 L in adults) ^[31]^A1c. For subsequent replacement, the 2024 consensus recommends balanced crystalloids (e.g., lactated Ringer's) over 0.9% saline because balanced solutions reduce hyperchloremic acidosis and may shorten DKA resolution ^[15]^A1a^[31]^A1c. A Cochrane meta-analysis of 15 RCTs found buffered solutions associated with lower mortality in critically ill adults (OR 0.86, 95% CI 0.74-0.99) ^[15]^A1a. In children, the PECARN DKA FLUID trial (N=1389 episodes) found no difference in neurologic outcomes between 0.9% vs 0.45% saline or rapid vs slow infusion rates, but isotonic fluids remain standard to avoid rapid osmotic shifts ^[53]^A1b. After the initial bolus, continue at 4-14 mL/kg/h based on corrected serum sodium and volume status, aiming to replace the deficit (typically 6-8 L in adults) over 24-48 hours ^[31]^A1c.

Step 2: Insulin Therapy

Begin intravenous regular insulin at 0.1 U/kg bolus (optional) followed by 0.1 U/kg/h continuous infusion ^[31]^A1c. The 2024 consensus states that a bolus is not necessary if the infusion is started immediately ^[40]^A1c. For mild DKA, subcutaneous rapid-acting insulin analogues (lispro, aspart) every 1-2 hours are an alternative; a Cochrane review of 5 RCTs (N=201) found no difference in time to resolution or hypoglycemia compared with IV insulin, but most participants had mild DKA and the evidence is low-certainty ^[169]^A1a. When glucose falls to 200-250 mg/dL, reduce insulin infusion to 0.02-0.05 U/kg/h and add dextrose 5-10% to maintain glucose 150-200 mg/dL until ketoacidosis resolves ^[31]^A1c. Do not stop insulin until the anion gap is normal and pH >7.3 ^[40]^A1c.

Step 3: Potassium Replacement

Begin potassium replacement when serum K+ <5.3 mEq/L, aiming for 4-5 mEq/L ^[31]^A1c. Add 20-30 mEq/L to each liter of IV fluid; if K+ <3.3 mEq/L, hold insulin and give 40 mEq/h until >3.3 mEq/L to avoid fatal arrhythmias ^[40]^A1c. Severe hypokalemia (≤2.5 mEq/L) during DKA treatment is associated with a 4.9-fold increase in inpatient mortality (aOR 4.9, 95% CI 1.3-18.8) ^[136]^B2b.

Step 4: Bicarbonate, Use Only in Extreme Acidosis

Do NOT administer bicarbonate unless pH <6.9 ^[31]^A1c. In adults with pH 6.9-7.0, the consensus recommends 100 mmol NaHCO₃ in 400 mL sterile water over 2 hours; for pH <6.9, 200 mmol over 2 hours ^[40]^A1c. Bicarbonate therapy does not improve outcomes and may worsen hypokalemia and intracellular acidosis ^[31]^A1c.

Step 5: Monitoring and Titration

Glucose: hourly until stable, then every 2 hours ^[31]^A1c.
Electrolytes (Na, K, Cl, bicarbonate): every 2-4 hours ^[40]^A1c.
Beta-hydroxybutyrate: every 2-4 hours; resolution defined as <0.3 mmol/L ^[31]^A1c.
Venous pH: every 2-4 hours until >7.3 ^[40]^A1c.

Step 6: Resolution and Transition to Subcutaneous Insulin

DKA resolves when glucose <200 mg/dL, pH >7.3, bicarbonate >15 mEq/L, and anion gap normal ^[31]^A1c. Transition to subcutaneous insulin when the patient is eating and the gap is closed. Overlap IV and SC insulin by 1-2 hours to prevent rebound hyperglycemia ^[40]^A1c. For patients on SGLT2 inhibitors, hold the drug during acute illness and restart only after metabolic stability, as SGLT2i increase DKA risk (IRR 2.59, 95% CI 1.57-4.27) and can cause euglycemic DKA ^[2]^A1a^[59]^D5^[157]^D5.

What NOT to Do

Do not use bicarbonate routinely, only for pH <6.9 ^[31]^A1c.
Do not stop insulin when glucose falls, add dextrose instead ^[40]^A1c.
Do not correct hyperosmolality too rapidly, risk of cerebral edema, especially in children ^[53]^A1b.
Do not delay insulin for hypokalemia, correct K+ first, then start insulin ^[40]^A1c.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
Fluid type for resuscitation	ADA/EASD 2024 consensus recommends balanced crystalloids (e.g., lactated Ringer's) over 0.9% saline ^[31]^A1c^[40]^A1c	PECARN trial found no difference in neurologic outcomes between 0.9% and 0.45% saline in children ^[53]^A1b	Moderate (adult vs pediatric evidence, different outcomes)	In adults, balanced solutions preferred; in children, isotonic fluids remain standard but choice may not affect neurologic outcomes
Subcutaneous vs IV insulin for mild DKA	Cochrane review found no difference in resolution time or hypoglycemia ^[169]^A1a	ADA/EASD consensus recommends IV insulin for moderate-severe DKA; SC may be used in mild DKA in monitored settings ^[31]^A1c	Mild (SC is an option for mild DKA, but evidence is low-certainty)	SC insulin can be considered in mild DKA with close monitoring; IV remains standard for moderate-severe
SGLT2 inhibitor use in type 1 diabetes	EASE trials showed 2.5 mg improved HbA1c without increased DKA (0.8% vs 1.2% placebo) ^[148]^A1b	Meta-analysis of CVOTs found SGLT2i increased DKA risk (IRR 2.59, 95% CI 1.57-4.27) ^[2]^A1a	Strong (dose-dependent risk; low-dose may be safer)	Low-dose SGLT2i (2.5 mg) may be considered as adjunct in type 1 diabetes with careful ketone monitoring; higher doses increase DKA risk

Pearl: Initiate fluid resuscitation before insulin to restore intravascular volume and improve tissue perfusion; delay insulin until serum potassium is >3.3 mEq/L to avoid fatal arrhythmias, and use balanced crystalloids to reduce hyperchloremic acidosis ^[15]^A1a^[31]^A1c^[40]^A1c.

Insulin Dosing Regimens for DKA

Regimen	Starting dose	Adjustment	Transition
IV regular insulin (standard)	0.1 U/kg bolus (optional) then 0.1 U/kg/h infusion	Reduce to 0.02-0.05 U/kg/h when glucose <200-250 mg/dL; add dextrose 5-10%	Overlap IV and SC by 1-2 hours when eating and gap closed
SC rapid-acting analogue (mild DKA)	0.3 U/kg lispro or aspart, then 0.1 U/kg every 1-2 h	Adjust based on glucose trend; continue until gap closed	Transition to basal-bolus SC regimen when stable
Pediatric IV insulin	0.05-0.1 U/kg/h (no bolus recommended)	Same as adult; reduce at glucose 200-250 mg/dL	Same overlap principle

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

▸Automated insulin delivery systems (closed-loop) significantly improve glycemic control and reduce DKA risk compared with multiple daily injections.
▸SGLT2 inhibitors improve HbA1c and weight but increase DKA risk; lower doses (e.g., empagliflozin 2.5 mg) may mitigate this risk.
▸Screening for presymptomatic type 1 diabetes and structured education reduce DKA at clinical onset.

! Warning: SGLT2 inhibitors are not FDA-approved for type 1 diabetes and carry a black-box warning for DKA risk. Use only with patient education on ketone monitoring and sick-day rules, and consider lower doses (e.g., empagliflozin 2.5 mg) to mitigate risk [148, 182].

Once the acute metabolic crisis is resolved, the focus shifts to preventing recurrence through a treat-to-target strategy that optimizes insulin delivery, addresses precipitating factors, and considers adjunctive or definitive therapies.

Insulin Replacement: Technology-Enabled Treat-to-Target

Basal-bolus insulin therapy remains the cornerstone of long-term , but technology has transformed its delivery. Continuous glucose monitoring (CGM) reduces the risk of subsequent DKA: in a nationwide cohort, CGM users had an adjusted hazard ratio of 0.40 (95% CI 0.33-0.48) for DKA compared with non-users ^[106]^B2b. Automated insulin delivery (AID) systems further improve outcomes. The ADAPT trial reported a mean HbA1c reduction of 1.54% (from 9.00% to) with advanced hybrid closed-loop therapy versus 0.20% with multiple daily injections plus intermittently scanned CGM ^[98]^A1b. The RADIANT trial showed that tubeless AID reduced HbA1c by 0.8% more than control (adjusted mean difference -0.8%, 95% CI -1.0 to -0.6) ^[99]^A1b. No DKA events occurred in either trial. In pregnancy, the AiDAPT trial demonstrated that hybrid closed-loop therapy increased time in the pregnancy-specific target range (63-140 mg/dL) from 55.6% to 68.2% (adjusted difference 10.5 percentage points) with only one DKA episode per group ^[21]^A1b. For young children aged 2-6 years, the LENNY trial showed AID increased time in range by 9.9 percentage points ^[151]^A1b. Early initiation of subcutaneous basal insulin during DKA treatment itself may shorten resolution time by a mean 4.06 hours without increasing adverse events ^[183]^A1a.

Suppression: Adjunctive Pharmacotherapy

Adjunctive agents can improve glycemic control but carry trade-offs. SGLT2 inhibitors reduce HbA1c and weight in type 1 diabetes but increase DKA risk. A meta-analysis of 16 RCTs reported a DKA risk ratio of 4.45 ^[175]^A1a. The EASE program found that 2.5 mg had a DKA rate comparable to placebo (0.8% vs 1.2%), whereas 10 mg and 25 mg doses had rates of 4.3% and 3.3%, respectively ^[148]^A1b. Lower doses may mitigate risk. GLP-1 receptor agonists such as modestly reduce HbA1c and weight without significantly increasing DKA ^[150]^A1b. A novel combination of an SGLT2 inhibitor ( 10 mg) with a glucagon receptor antagonist (volagidemab 70 mg weekly) improved time in range to 86% and reduced peak β-hydroxybutyrate during insulin withdrawal compared with SGLT2i alone (2.0 vs 2.4 mmol/L; P=0.048) ^[20]^A1b. DPP-4 inhibitors have also been studied: sitagliptin 50 mg added to advanced hybrid closed-loop therapy in adolescents improved time in range and reduced urinary albumin-to-creatinine ratio without DKA events ^[156]^A1b.

Definitive Therapies: Transplantation and Immunomodulation

Pancreas or islet transplantation restores endogenous insulin secretion and eliminates DKA risk but requires lifelong immunosuppression. Immunomodulation offers a less invasive alternative. Teplizumab, an anti-CD3 monoclonal antibody, preserves β-cell function in stage 2 type 1 diabetes: a meta-analysis of 5 RCTs showed a standardized mean difference in C-peptide AUC of 0.28 (95% CI 0.09-0.48) at 9-15 months, with no increase in DKA (RR 0.80) ^[128]^A1a. The combination of anti-IL-21 antibody and liraglutide preserved C-peptide at 54 weeks (estimated treatment ratio 1.48 vs placebo;) ^[150]^A1b. These therapies are currently reserved for recent-onset disease or those with residual β-cell function.

Prevention Through Screening and Education

Screening for islet autoantibodies in presymptomatic children dramatically reduces DKA at clinical onset: only 2.5% of screened children presented with DKA versus unscreened controls ^[88]^B2b. Structured diabetes education and telemonitoring also lower DKA rates. In a randomized trial, telecounseling reduced DKA episodes from 18% to 1.7% (P=0.001) ^[168]^A1b. Continuous ketone monitoring (CKM) is emerging as a tool for early detection; expert consensus recommends action thresholds of ≥0.6 mmol/L for caution and ≥1.0 mmol/L for medical contact ^[163]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
SGLT2i use in type 1 diabetes	ADA/EASD 2021 consensus recommends against routine use due to DKA risk; only with caution and ketone monitoring ^[130]^A1c	Endocrine Society meta-analysis shows benefit in HbA1c and weight, but DKA risk RR 4.45 ^[175]^A1a	Moderate	Off-label use requires shared decision-making, patient education, and low-dose strategies (e.g., empagliflozin 2.5 mg)
Closed-loop vs standard care	NICE recommends AID for all with type 1 diabetes who meet criteria	Some health systems limit access due to cost	Mild	Increasing evidence supports AID as standard of care; cost-effectiveness analyses are needed

Pearl: Preventing DKA recurrence requires a three-pronged approach: optimize insulin delivery with technology (CGM + AID), consider low-dose SGLT2i with rigorous ketone monitoring for selected patients, and screen at-risk populations to enable early intervention.

Adjunctive Agents in Type 1 Diabetes: Dosing and DKA Risk

Agent	Dose	HbA1c reduction	DKA risk vs placebo	Key trial
Empagliflozin 2.5 mg	2.5 mg daily	-0.28%	0.8% vs 1.2% (NS)	EASE-3 ^[148]^A1b
Empagliflozin 10 mg	10 mg daily	-0.54%	4.3% vs 1.2%	EASE-2/3 ^[148]^A1b
Empagliflozin 25 mg	25 mg daily	-0.53%	3.3% vs 1.2%	EASE-2/3 ^[148]^A1b
Dapagliflozin 5 mg	5 mg daily	-0.42%	Increased (RR 4.45 overall)	DEPICT-1 ^[179]^A1b
Dapagliflozin 10 mg	10 mg daily	-0.45%	Increased	DEPICT-1 ^[179]^A1b
Liraglutide	1.8 mg daily	-0.50%	Not significantly increased	^[150]^A1b
Sitagliptin	50 mg daily	Improved TIR	No DKA events	^[156]^A1b

History and Evolution of Treatment

▸Low-dose insulin therapy (5-10 U/h) replaced high-dose regimens after the 1977 Fisher trial, reducing hypoglycemia without compromising efficacy.
▸Routine phosphate administration was abandoned after a 1983 trial showed no clinical benefit and increased hypocalcemia.
▸Closed-loop insulin delivery systems improve time-in-range by 10-12 percentage points over standard therapy, with minimal DKA risk in contemporary trials.

HY High Yield: The PECARN trial definitively showed that neither fluid rate nor sodium content affects neurologic outcomes in pediatric DKA, ending decades of debate [53].

The evolution of DKA over the past five decades reflects a shift from high-dose insulin regimens to evidence-based protocols emphasizing safety and precision. Before the discovery of insulin, DKA was uniformly fatal. The introduction of insulin in the 1920s transformed the prognosis, but early protocols used high-dose insulin (50-100 U/h), which caused frequent hypoglycemia and hypokalemia. The landmark trial by Fisher and Kitabchi in 1977 established low-dose insulin therapy as the standard: 45 patients with DKA were randomized to intravenous, subcutaneous, or intramuscular insulin, all receiving an initial priming dose followed by 5-10 U/h ^[197]^A1b. The intravenous group had a more rapid fall in plasma glucose (P < 0.01) and ketone bodies (P < 0.05) during the first two hours, but thereafter no significant differences in recovery time were observed ^[197]^A1b. Low-dose insulin reduced hypoglycemia risk and remains the cornerstone of DKA treatment.

Phosphate therapy was next scrutinized. In a randomized trial of 30 DKA patients, Fisher and Kitabchi (1983) compared phosphate infusion (8.5 mmol/h) versus no phosphate. Phosphate therapy accelerated regeneration of erythrocyte 2,3-DPG but had no demonstrable influence on tissue oxygenation or clinical response, and it significantly lowered plasma ionized calcium ^[185]^A1b. Consequently, routine phosphate administration was abandoned.

The fluid resuscitation debate, whether rapid or slow administration, and whether 0.9% or 0.45% saline, was resolved by the PECARN DKA FLUID trial (2018), which randomized 1389 DKA episodes in children to four factorial combinations. Neither the rate nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes ( decline to <14 occurred in 3.5% of episodes, clinically apparent brain injury in 0.9%) ^[53]^A1b. Current guidelines recommend isotonic fluids with careful monitoring of neurologic status.

Adjunctive therapies emerged in the 2010s. Sodium-glucose cotransporter 2 (SGLT2) inhibitors improved glycemic control in type 1 diabetes but increased DKA risk. In DEPICT-1 (2017), 5 mg and 10 mg reduced HbA1c by 0.42% and 0.45% versus placebo, respectively, but DKA occurred in 3-4% of treated patients ^[179]^A1b. The EASE trials (2018) with showed that a 2.5 mg dose had a DKA rate comparable to placebo (0.8% vs 1.2%), while 10 mg and 25 mg increased DKA to 4.3% and 3.3% (NNH ≈ 32 and 48, respectively) ^[148]^A1b. Sotagliflozin, a dual SGLT1/2 inhibitor, improved HbA1c but also raised DKA risk (3.0% vs 0.6% in inTandem3) ^[180]^A1b. Glucagon-like peptide-1 receptor agonists (e.g., ) and combination therapies (e.g., anti-IL-21 + liraglutide) have shown promise in preserving β-cell function without increasing DKA ^[150]^A1b.

Automated insulin delivery (AID) systems represent the most recent paradigm shift. The iDCL trial (2019) demonstrated that closed-loop control increased time-in-range (70-180 mg/dL) by 11 percentage points over sensor-augmented pump therapy (71% vs 59%) with no severe hypoglycemia and one DKA episode ^[154]^A1b. Subsequent trials in young children (PEDAP, 2023), pregnancy (AiDAPT, 2023), and older adults (ORACL, 2022) confirmed similar benefits ^[101]^A1b^[21]^A1b^[193]^A1b. The RADIANT trial (2026) showed that transitioning from multiple daily injections to tubeless AID reduced HbA1c by 0.8% (from 8.1% to 7.2%) with no DKA ^[99]^A1b. Emerging strategies include low-dose empagliflozin (2.5-5 mg) as adjunct to closed-loop, which increased time-in-range by 11-13 percentage points without DKA ^[194]^A1b, and combination SGLT2 inhibitor plus glucagon receptor antagonist, which improved glycemia while attenuating ketogenesis ^[20]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should SGLT2 inhibitors be used in type 1 diabetes?	ADA/ES: Consider in select patients with close monitoring for DKA ^[148]^A1b^[179]^A1b	EMA: Contraindicated in type 1 diabetes due to DKA risk	Moderate	Use only with ketone monitoring and low doses (e.g., empagliflozin 2.5 mg)
What is the optimal fluid rate for pediatric DKA?	PECARN trial: No difference between rapid and slow rates ^[53]^A1b	Some guidelines still recommend cautious rehydration	Strong	Individualize based on clinical status; avoid cerebral edema

Pearl: The mortality of DKA has fallen from nearly 100% in the pre-insulin era to <1% today, driven by low-dose insulin, judicious fluid resuscitation, and, most recently, automated insulin delivery; the next frontier is preventing DKA through early detection and adjunctive therapies that mitigate ketogenesis without increasing risk.

Landmark Trials in DKA Treatment Evolution

Trial (Year)	Intervention	Key Finding	Impact on Practice
Fisher & Kitabchi (1977) ^[197]^A1b	Low-dose IV vs SC vs IM insulin	IV route faster initial glucose decline; all routes effective	Established low-dose insulin as standard
Fisher & Kitabchi (1983) ^[185]^A1b	Phosphate vs no phosphate	No clinical benefit; increased hypocalcemia	Phosphate therapy abandoned
PECARN DKA FLUID (2018) ^[53]^A1b	Rapid vs slow fluid; 0.9% vs 0.45% saline	No difference in neurologic outcomes	Fluid rate and tonicity not critical for brain injury
DEPICT-1 (2017) ^[179]^A1b	Dapagliflozin 5/10 mg vs placebo	HbA1c ↓ 0.42-0.45%; DKA ↑	SGLT2i use in T1D requires caution
EASE (2018) ^[148]^A1b	Empagliflozin 2.5/10/25 mg vs placebo	2.5 mg: DKA comparable to placebo; 10/25 mg: DKA ↑	Low-dose empagliflozin may be safer
iDCL (2019) ^[154]^A1b	Closed-loop vs sensor-augmented pump	TIR ↑ 11 percentage points; no severe hypoglycemia	Closed-loop becomes standard of care
RADIANT (2026) ^[99]^A1b	Tubeless AID vs MDI	HbA1c ↓ 0.8%; no DKA	Supports AID as first-line therapy

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

▸DKA can be the first clue to an autoimmune polyendocrine syndrome (type B insulin resistance, ICPi-induced APS-2) or monogenic diabetes (HNF1A-MODY, neonatal diabetes, KPD, Klinefelter, Cohen).
▸COVID-19 acts as a co-axis stressor, worsening insulin resistance and increasing DKA incidence in both type 1 and type 2 diabetes.
▸Thyroid and adrenal axes are commonly perturbed during DKA (euthyroid sick syndrome, thyroid storm, Cushing syndrome); interpret abnormal tests with caution and repeat after metabolic stabilization.

HY High Yield: The Abeta classification of ketosis-prone diabetes (KPD) separates patients by autoantibody status (A+ vs A-) and β-cell function (β+ vs β-). The A-β+ phenotype is common in non-white populations and often achieves insulin independence after the acute DKA episode [13].

Dx Diagnostic Essentials: In any patient on immune checkpoint inhibitors who presents with DKA, immediately assess for concomitant adrenal insufficiency (cortisol, ACTH) and thyroid dysfunction (TSH, FT4). APS-2 can cause life-threatening adrenal crisis if missed [114].

The recognition that DKA can be the presenting manifestation of an underlying multiglandular or monogenic syndrome has grown in parallel with advances in genetic testing and immunotherapy. Endocrine lesions rarely sit in isolation: they cluster in inherited tumor syndromes and perturb adjacent axes, so the clinician must maintain a low threshold for syndromic screening and cross-axis surveillance.

Autoimmune Polyendocrine Syndromes

Type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor, can present with severe DKA despite massive exogenous insulin doses. In a reported case, a 39-year-old woman with systemic lupus erythematosus required and pulse-dose to achieve euglycemic remission, maintained on azathioprine ^[25]^C4. Immune checkpoint inhibitors (ICPis), particularly PD-1 inhibitors, can trigger autoimmune polyendocrine syndrome type 2 (APS-2), manifesting as DKA and acute adrenal crisis. Patients with the HLA-DR4 allele are at highest risk and require close monitoring after ICPi initiation ^[114]^C4.

Monogenic and Syndromic Diabetes

Syndrome	Gene / Mechanism	DKA Context	Key Feature
HNF1A-MODY	HNF1A mutation	DKA can occur with severe dehydration and noncompliance; does not exclude MODY ^[4]^C4	Low renal threshold for glucose; sulfonylurea-responsive
Neonatal diabetes (6q24)	Chromosome 6q24 abnormality	Lower frequency of DKA at onset vs KCNJ11; macroglossia common ^[84]^C4	Transient form; resolves within months
Neonatal diabetes (KCNJ11)	KCNJ11 mutation	Higher DKA risk; may include epilepsy and developmental delay ^[84]^C4	Permanent; may respond to sulfonylureas
Ketosis-prone diabetes (KPD)	A-β+ phenotype (autoantibody-negative, preserved C-peptide)	DKA precipitated by stress (e.g., high-altitude hypoxia, severe infection) ^[13]^D5^[214]^C4	Insulin independence after acute episode
	47,XXY	DKA as initial presentation of diabetes; associated with metabolic syndrome ^[215]^C4	Small testes, infertility,
Cohen syndrome	VPS13B biallelic variants	Early-onset insulin-resistant diabetes with recurrent DKA; negative islet autoantibodies ^[216]^C4	Intellectual disability, neutropenia, retinal dystrophy

Co-Axis Endocrine Effects

Cushing syndrome due to an ACTH-secreting pheochromocytoma can present with DKA. A glucocorticoid-driven positive-feedback loop, dexamethasone paradoxically increased ACTH secretion, exacerbated hypercortisolemia and ketoacidosis ^[27]^C4. is another mimic: a 71-year-old woman with Graves disease presented with DKA and Takotsubo cardiomyopathy, diagnosed only after cardiac catheterization ^[80]^C4. Euthyroid sick syndrome (ESS) is highly prevalent in pediatric DKA (61.5% in one cohort), with two phenotypes: isolated low FT3 (35.7%) and combined low FT4/FT3 (64.3%). Complete biochemical recovery within two weeks is not universal (38.4% FT3 normalization), so thyroid function tests during acute DKA must be interpreted cautiously to avoid misdiagnosis of primary thyroid disease ^[94]^B3b.

as a Co-Axis Perturbation

The SARS-CoV-2 pandemic unmasked a striking co-axis effect: youth with new-onset type 2 diabetes had a DKA incidence of 20% in 2020 versus 3-9% in prior years ^[211]^C4^[87]^B3b. Among children with established type 1 diabetes, COVID-19 infection reduced tissue glucose disposal by 46% during DKA treatment, indicating direct exacerbation of insulin resistance ^[212]^B3b. SARS-CoV-2 may also impair β-cell function, contributing to new-onset diabetes and DKA ^[71]^D5^[63]^D5.

Pearl: In any patient with atypical DKA, negative autoantibodies, preserved C-peptide, recurrent episodes, or a family history of diabetes, pursue genetic testing for monogenic diabetes and screen for autoimmune polyendocrine syndromes, especially if the patient is on immune checkpoint inhibitors.

Complications and Long-term Sequelae

▸Hypokalemia ≤ 2.5 mEq/L and severe hypoglycemia < 40 mg/dL during DKA therapy each carry a ~4.9-fold increase in inpatient mortality.
▸SGLT2 inhibitors increase DKA risk 2.2- to 4.5-fold; these agents should be held during acute illness, surgery, or before procedures.
▸Continuous glucose monitoring and automated insulin delivery reduce DKA-related hospitalizations by 40-60% and are central to long-term prevention.

! Warning: SGLT2 inhibitors are now recognized as a common precipitant of euglycemic DKA. Patients presenting with nausea, vomiting, or malaise, even with glucose < 250 mg/dL, should have a capillary ketone measurement [59].

HY High Yield: Intentional insulin omission (diabulimia) affects 20-45% of adolescents and young adults with type 1 diabetes and is a major driver of recurrent DKA. Screen all patients with recurrent DKA using the DEPS-R [220].

Multiglandular involvement amplifies the metabolic derangement, but the acute crisis itself, and its treatment, carries a burden of complications that extend well beyond the admission. The most feared short-term complication of DKA therapy is cerebral edema, occurring in 0.5-1% of pediatric episodes and up to 15-20% of fatal cases ^[166]^D5. Hypokalemia from aggressive insulin-driven intracellular shift is equally dangerous: serum potassium ≤ 2.5 mEq/L during treatment is associated with a 4.9-fold increase in inpatient mortality (aOR 4.9, 95% CI 1.3-18.8) ^[136]^B2b. Severe hypoglycemia (< 40 mg/dL) during carries a similar 4.8-fold mortality risk ^[136]^B2b. Avoiding these iatrogenic complications requires strict adherence to potassium replacement thresholds and hourly glucose monitoring.

Acute Complications of DKA Therapy

Complication	Frequency	Prevention	Management
Cerebral edema	0.5-1% (pediatric)	Avoid rapid overcorrection of osmolality; maintain gradual decline in glucose ^[166]^D5	Mannitol 0.25-1 g/kg IV, hyperventilation, ICU care
Hypokalemia (≤ 2.5 mEq/L)	55% of admissions (any degree)	Replace potassium when serum falls below 5.5 mEq/L; hold insulin if K < 3.3 mEq/L ^[136]^B2b	IV KCl 20-40 mEq/h; monitor ECG
Severe hypoglycemia (< 40 mg/dL)	4-10% of treated episodes	Hourly glucose checks; adjust insulin infusion rate ⬇ when glucose falls < 250 mg/dL ^[136]^B2b	50% dextrose 25 g IV or glucagon; restart insulin when glucose rises
	40-60% with 0.9% saline	Use balanced crystalloids (e.g., lactated Ringer’s) ^[15]^A1a	Resolves with switch to balanced fluids; no specific therapy
Acute kidney injury	5-15%	Volume resuscitation before insulin; avoid SGLT2i in eGFR < 45 ^[170]^A1a	Supportive; renal replacement if severe

Long-term Sequelae and Recurrence

Recurrent DKA is a marker of high-risk disease. In the DPV registry (2011-2013), the rate of DKA admission among young people with established type 1 diabetes was 4.81 per 100 patient-years, with the highest rates in adolescents aged 15-20 years (6.21 per 100 patient-years) and those with HbA1c ≥ 9% (15.83 per 100 patient-years) ^[69]^B2b. More recent data from 2013-2022 show a decline to 2.2 per 100 patient-years in children, attributed to wider use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) ^[164]^B2b. CGM use is associated with a 60% reduction in DKA-related hospitalizations (aHR 0.40, 95% CI 0.33-0.48) ^[106]^B2b.

DKA as a complication of pharmacotherapy has emerged as a critical safety signal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) increase DKA risk 2.2- to 4.5-fold across trials, with an absolute incidence of 0.3-0.9% in type 2 diabetes ^[2]^A1a^[51]^A1a^[152]^A1b^[153]^A1b^[167]^B2b. The risk is accentuated by precipitating factors such as reduced oral intake, surgery, or infection, leading to guidelines recommending SGLT2i hold during acute illness ^[59]^D5. Antipsychotic agents, particularly second-generation drugs like olanzapine and clozapine, are associated with DKA (OR 2.60, 95% CI 1.06-6.38) ^[66]^B3b^[219]^B2a. Immune checkpoint inhibitors (e.g., anti-PD-1) can precipitate fulminant DKA, sometimes within days of therapy initiation ^[202]^C4.

Mortality and long-term outcomes. In-hospital mortality from isolated DKA is approximately 1-2%, but rises to 9-17% when combined with hyperosmolar hyperglycemic state (HHS) ^[55]^B2b^[136]^B2b. Patients with a history of DKA have a 4.2-year reduction in life expectancy at age 40 compared with normoglycemic individuals ^[160]^B2b. Chronic pancreatitis confers a 9.5-fold higher risk of DKA and a 2.43-fold higher mortality (HR 2.43, 95%) ^[218]^B2b.

Prevention Strategies

Diabetes technology: CGM and AID systems reduce DKA risk by 40-60% ^[106]^B2b^[108]^D5. Telemonitoring programs can lower DKA episodes from 18% to 1.7% in pediatric populations ^[168]^A1b.
Sick-day rules: Patients on SGLT2i should temporarily discontinue the drug during febrile illness, illness, or before surgery ^[59]^D5.
Psychosocial screening: Intentional insulin omission (diabulimia) affects 20-45% of young adults with type 1 diabetes and is a major driver of recurrent DKA; screening with the Diabetes Eating Problem Survey-Revised (DEPS-R) is recommended ^[220]^B2a.

Pearl: The strongest predictor of a future DKA event is a prior DKA event, especially in adolescents with HbA1c > 9%, making targeted education, technology access, and psychosocial support the most effective long-term prevention tools ^[69]^B2b.

Prognosis, Natural History and Prevention

▸DKA remains common in longstanding type 1 diabetes (1.4-1.8 events/100 person-years); predictors include poor glycemic control, nephropathy, cardiovascular events, and foot ulcer/amputation.
▸Structured diabetes education reduces DKA rates; disease-modifying therapies (teplizumab, anti-IL-21 + liraglutide) preserve β-cell function and delay progression.
▸Population-based islet autoantibody screening reduces DKA at diagnosis to <3% and is cost-effective when combined with monitoring and education.

HY High Yield: A prior major adverse cardiovascular event (HR 3.16) or foot ulcer/amputation (HR 1.59) independently predicts future DKA, these patients need targeted prevention [224].

The long-term trajectory after a DKA episode is shaped by modifiable risk factors and the presence of diabetes complications, which themselves increase future DKA risk ^[224]^B2b. In adults with longstanding type 1 diabetes, DKA remains a common cause of hospitalization, with an incidence of 1.4 to 1.8 events per 100 person-years ^[54]^B2b. The majority of patients are hospitalized only once, but the frequency has increased modestly over time (~2.4% per year) ^[54]^B2b. Predictors include poor glycemic control, insulin pump use, smoking, alcohol consumption, and diabetic nephropathy, patients with end-stage renal disease have a 2.09-fold higher risk compared with those with normal albumin excretion ^[54]^B2b. Major adverse cardiovascular events (HR 3.16, 95%) and late-stage neuropathy (foot ulcer or amputation; HR 1.59, 95%) independently predict future DKA, independent of HbA1c and insulin dose ^[224]^B2b. Female sex (HR 2.04) and higher time-updated HbA1c (per 1%: HR 1.39) also confer increased risk ^[224]^B2b. In young children, a single episode of moderate-to-severe DKA at diagnosis is associated with lower cognitive scores and altered brain growth over 18 months ^[142]^B2b.

Prevention Strategies

Structured diabetes self- education reduces DKA rates ^[70]^D5. For individuals with established type 1 diabetes, prevention focuses on identifying those at risk, adolescents aged 13-25 years, females, those with prior DKA, psychiatric comorbidities (eating disorders, depression), and socioeconomic disadvantage ^[70]^D5. When adjunct therapies with elevated DKA risk (e.g., SGLT2 inhibitors) are considered, risk mitigation strategies must be in place ^[70]^D5. In patients with type 1 diabetes undergoing bariatric surgery, insulin must never be stopped to prevent DKA ^[67]^A1c. Disease-modifying therapies can alter the natural history: teplizumab, an anti-CD3 monoclonal antibody, delays progression from stage 2 to stage 3 type 1 diabetes and preserves β-cell function (C-peptide AUC SMD 0.28, 95% CI 0.09-0.48) with a modest reduction in insulin dose (-0.11 U/kg/day) and HbA1c (-) ^[128]^A1a. Combination therapy with anti-IL-21 antibody and also preserves stimulated C-peptide at 54 weeks (estimated treatment ratio 1.48, 95%) ^[150]^A1b.

Screening and Early Detection

Population-based screening for islet autoantibodies (GADA, IA-2A, ZnT8A, IAA) identifies individuals with presymptomatic (stage 1 and 2) type 1 diabetes ^[116]^D5^[131]^A1c. Children diagnosed through screening have markedly milder clinical presentation at stage 3: median HbA1c 6.8% vs 10.5%, ketonuria in 22.2% vs 78.4%, and DKA in only 2.5% vs unscreened cohorts ^[88]^B2b. In relatives screened and followed, no DKA occurred at onset among those who progressed to stage 3 ^[76]^B2b. Screening programs are cost-effective if they reduce DKA events by ≥20% and improve lifetime HbA1c by ≥0.1% ^[223]^B2c. Parents and pediatricians prioritize monitoring programs that reduce DKA risk to 1% and availability of treatments that delay insulin dependence ^[222]^D5. Cascade screening of first-degree relatives (aged 1-45 years) and second-degree relatives (aged 1-20 years) is recommended, with periodic autoantibody testing, metabolic monitoring, and education ^[76]^B2b^[131]^A1c.

Pearl: The strongest independent predictor of future DKA is a prior major adverse cardiovascular event (HR 3.16), patients with established macrovascular disease should be targeted for intensified DKA prevention education and self-management support ^[224]^B2b.

Special Populations, Pregnancy and Fertility

▸Pediatric DKA management requires careful fluid resuscitation and monitoring for cerebral edema; CGM and AID reduce DKA risk by over 50%.
▸DKA in pregnancy carries 17% fetal loss; closed-loop insulin delivery improves outcomes without increasing DKA.
▸In elderly and immunocompromised patients, SGLT2i must be withheld during acute illness to prevent euglycemic DKA.

! Warning: SGLT2 inhibitors are contraindicated in pregnancy and must be withheld 3-4 days before elective surgery or during acute illness in all patients to prevent euglycemic DKA [59,67].

Building on the prognostic data, the of DKA must be tailored across the lifespan and in special physiologic states, where presentation, diagnostic thresholds, and treatment strategies diverge from standard adult care.

Pediatrics

Approximately 41.9% of children with new-onset type 1 diabetes present in DKA globally, with rates rising in the United States from 41% to 58% between 2010 and 2017 ^[77]^B2a^[120]^B2b. Younger age and female sex independently increase risk ^[77]^B2a. infection exacerbates insulin resistance during DKA, reducing tissue glucose disposal by 46% compared with COVID-negative peers ^[212]^B3b. The PECARN DKA FLUID trial (n=1389 episodes) demonstrated that neither the rate of fluid administration nor the sodium chloride content (0.9% vs 0.45%) significantly influenced neurologic outcomes, including cerebral edema ^[53]^A1b. Balanced electrolyte solutions may reduce hyperchloremia and acute kidney injury, though differences did not reach statistical significance in a small randomized trial ^[74]^A1b. Continuous glucose monitoring (CGM) reduces DKA risk by 56% (adjusted HR 0.44, 95% CI 0.35-0.56) in children and adolescents ^[237]^B2b. Automated insulin delivery (AID) systems increase time-in-range by 9.88% (2.37 h/day) in children <7 years without increasing DKA ^[229]^B2a. Telemonitoring programs lower DKA rates from 18% to 1.7% ^[168]^A1b. DKA at diagnosis is associated with persistently higher HbA1c at 1 and 2 years, but AID use moderates this effect ^[121]^B2b.

Pregnancy

DKA in pregnancy is an obstetric emergency: in a retrospective cohort of 58 pregnancies, fetal demise occurred in 17.2% (6 miscarriages, 4 stillbirths), preeclampsia in 29.3%, and neonatal hypoglycemia in 60.4% ^[58]^B3b. Women with type 2 diabetes have lower DKA risk (OR 0.09, 95%) but paradoxically higher perinatal mortality (OR 1.50) compared with type 1 ^[217]^A1a. The AiDAPT trial demonstrated that hybrid closed-loop therapy significantly improved pregnancy-specific time-in-range (68.2% vs 55.6%; adjusted difference 10.5 percentage points, P<0.001) with only one DKA event per group ^[21]^A1b. Insulin pump use in pregnancy is associated with lower HbA1c without increased DKA or severe hypoglycemia ^[235]^B2b. Closed-loop insulin delivery is also effective intrapartum and postpartum, reducing hypoglycemia without DKA ^[232]^A1b^[176]^A1b. SGLT2 inhibitors are contraindicated in pregnancy due to risk of euglycemic DKA and potential fetal harm ^[59]^D5. is safe with insulin therapy; closed-loop systems reduce postpartum hypoglycemia ^[176]^A1b.

Elderly

Older adults (≥65 years) with type 1 diabetes have higher mortality from hyperosmolar hyperglycemic state (10-20%) than from DKA ^[62]^D5. The MiniMed 780G advanced hybrid closed-loop system improved time-in-range from 57.4% to 79.7% over 12 months in adults ≥65 years with no episodes of DKA or severe hypoglycemia ^[234]^A1b. In the DECLARE- 58 trial, efficacy and safety were consistent across age subgroups, but DKA was more frequent with dapagliflozin versus placebo without age heterogeneity (interaction P=0.84) ^[228]^A1b. SGLT2i should be withheld during acute illness to prevent euglycemic DKA, especially in elderly patients with renal impairment or polypharmacy ^[59]^D5. Insulin doses may require reduction due to declining renal function.

Immunocompromised

Infections, particularly COVID-19, precipitate DKA through stress-hormone-mediated insulin resistance. COVID-19-positive children with DKA had 46% lower tissue glucose disposal than COVID-negative controls, indicating a direct metabolic derangement ^[212]^B3b. The pandemic also saw a spike in DKA at diagnosis of type 2 diabetes in youth (20% vs 3-9% in prior years) ^[211]^C4. For immunocompromised patients (transplant, HIV, chronic steroid use), insulin must never be discontinued in type 1 diabetes ^[67]^A1c. SGLT2i should be held 3-4 days before elective surgery and during any intercurrent illness to reduce DKA risk ^[59]^D5^[67]^A1c. Continuous ketone monitoring may facilitate early detection of euglycemic DKA in this vulnerable population ^[163]^D5.

Pearl: In pregnant women with type 1 diabetes, closed-loop insulin delivery improves glycemic control without increasing DKA risk and should be continued through labor and postpartum; in elderly and immunocompromised patients, SGLT2i must be withheld during acute illness to prevent euglycemic DKA.

References

[1]
Wu L, Tsang V, Menzies AM et al.. “Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.” Diabetes care (2023). PMID: 37220262 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[2]
Marilly E, Cottin J, Cabrera N et al.. “SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.” Diabetologia (2022). PMID: 35925319 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[3]
Usher-Smith JA, Thompson M, Ercole A et al.. “Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review.” Diabetologia (2012). PMID: 22933123 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[4]
Pruhova S, Dusatkova P, Neumann D et al.. “Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY?” Diabetes care (2013). PMID: 23610083 ↗
L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[5]
Raubenheimer PJ, Skelton J, Peya B et al.. “Phenotype and predictors of insulin independence in adults presenting with diabetic ketoacidosis: a prospective cohort study.” Diabetologia (2024). PMID: 38240751 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[6]
Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature
[7]
Jahoor F, Hsu JW, Keene KR et al.. “Amino Acids and CART Distinguish A-β+ Ketosis-Prone Diabetes From Type 1 and Type 2 Diabetes During Hyperglycemic Crises.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39820433 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature
[8]
Balasubramanyam A, Garza G, Rodriguez L et al.. “Accuracy and predictive value of classification schemes for ketosis-prone diabetes.” Diabetes care (2006). PMID: 17130187 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature
[9]
Hampp C, Swain RS, Horgan C et al.. “Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.” Diabetes care (2019). PMID: 31601640 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature
[10]
Sheikh-Ali M, Karon BS, Basu A et al.. “Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?” Diabetes care (2008). PMID: 18184896 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature
[11]
Mulukutla SN, Acevedo-Calado M, Hampe CS et al.. “Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of "A+" Subtypes of Ketosis-Prone Diabetes.” Diabetes care (2018). PMID: 30327357 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature
[12]
Chobot A, Bossowski A, Jarosz-Chobot P et al.. “Polish Recommendations for the Early Detection of Type 1 Diabetes in the Pediatric Population: A Position Statement of the Polish Society of Pediatric Endocrinology and Diabetology and the Pediatric Section of the Diabetes Poland 2026.” Hormone research in paediatrics (2026). PMID: 41999619 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[13]
Balasubramanyam A, Nalini R, Hampe CS et al.. “Syndromes of ketosis-prone diabetes mellitus.” Endocrine reviews (2008). PMID: 18292467 ↗
L5CASE_REPORTCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[14]
Kovacs A, Bunduc S, Veres DS et al.. “One third of cases of new-onset diabetic ketosis in adults are associated with ketosis-prone type 2 diabetes-A systematic review and meta-analysis.” Diabetes/metabolism research and reviews (2023). PMID: 37888894 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
[15]
Delgado Moya FP, Antequera A, Muriel A et al.. “Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children.” The Cochrane database of systematic reviews (2026). PMID: 42011817 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[16]
Tian B, Chen C, Cheng J et al.. “Predictors, Morbidity, and Healthcare Costs of Acute Kidney Injury in Diabetic Ketoacidosis: A Decade-Long Retrospective Cohort Study of 464,057 US Hospitalizations.” Shock (Augusta, Ga.) (2025). PMID: 40550726 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature
[17]
Warncke K, Eckert A, Bonifacio E et al.. “Characterisation and clinical outcomes in children and adolescents with diabetes according to newly defined subgroups: a cohort study from the DPV registry.” EClinicalMedicine (2023). PMID: 37731934 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature
[18]
Zhang X, Huang D, Lou D et al.. “Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review.” BMC endocrine disorders (2024). PMID: 39218880 ↗
L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
[19]
Fisker FA, Voss TS, Svart MV et al.. “Insulin Signaling Is Preserved in Skeletal Muscle During Early Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37554078 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[20]
Boeder SC, Thomas RL, Le Roux MJ et al.. “Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.” Diabetes care (2025). PMID: 38776437 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[21]
Lee TTM, Collett C, Bergford S et al.. “Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 37796241 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[22]
de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[23]
Bangshaab M, Svart MV, Rittig N et al.. “Metabolic effects of 3-hydroxybutyrate infusion in individuals with type 1 diabetes compared with healthy control participants: a randomised crossover trial showing intact feedback suppression of lipolysis.” Diabetologia (2025). PMID: 40210728 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[24]
Colombijn JMT, de Leijer JF, Visseren FLJ et al.. “Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies.” Diabetologia (2025). PMID: 41117973 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[25]
Willard D, Upadhyay J, Kim C et al.. “Diabetic Ketoacidosis Without Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27636019 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[26]
Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[27]
Sakuma I, Higuchi S, Fujimoto M et al.. “Cushing Syndrome Due to ACTH-Secreting Pheochromocytoma, Aggravated by Glucocorticoid-Driven Positive-Feedback Loop.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26700559 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[28]
Kitabchi AE, Umpierrez GE, Fisher JN et al.. “Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18270259 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[29]
Burckhardt MA, Gotta V, Beglinger S et al.. “Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32835363 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[30]
Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[31]
Umpierrez GE, Davis GM, ElSayed NA et al.. “Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.” Diabetes care (2024). PMID: 39052901 ↗
L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[32]
Agiostratidou G, Anhalt H, Ball D et al.. “Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange.” Diabetes care (2017). PMID: 29162582 ↗
L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Special Populations, Pregnancy and Fertility
[33]
Wilding JP, Rajeev SP, DeFronzo RA. “Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.” Diabetes care (2016). PMID: 27440828 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[34]
Patorno E, Pawar A, Bessette LG et al.. “Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.” Diabetes care (2021). PMID: 33495295 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[35]
Haaland WC, Scaduto DI, Maldonado MR et al.. “A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome.” Diabetes care (2009). PMID: 19228875 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[36]
Knip M, Parviainen A, Turtinen M et al.. “SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study.” The lancet. Diabetes & endocrinology (2023). PMID: 36958868 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
[37]
Bugbee A, Rucinsky R, Alvarez E et al.. “2026 AAHA Diabetes Management Guidelines for Cats.” Journal of the American Animal Hospital Association (2026). PMID: 42014100 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[38]
Brown E, Heerspink HJL, Cuthbertson DJ et al.. “SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.” Lancet (London, England) (2021). PMID: 34216571 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[39]
Moreno-Pérez Ó, Tejera-Muñoz A, Leiva-Mora N et al.. “Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.” Cardiovascular diabetology (2026). PMID: 41913157 ↗
L2TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
[40]
Umpierrez GE, Davis GM, ElSayed NA et al.. “Hyperglycaemic crises in adults with diabetes: a consensus report.” Diabetologia (2024). PMID: 38907161 ↗
L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[41]
Anson M, Zhao SS, Austin P et al.. “SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.” Diabetologia (2023). PMID: 37505282 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[42]
McCrimmon RJ, Henry RR. “SGLT inhibitor adjunct therapy in type 1 diabetes.” Diabetologia (2018). PMID: 30132030 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[43]
Gruber N, Rathaus M, Ron I et al.. “Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes.” Diabetologia (2021). PMID: 34806114 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[44]
Sun WT, Liu RX, Jiang YH et al.. “Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42426564 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[45]
Wójcik-Sosnowska E, Tabeau A, Pawlik A et al.. “Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.” International journal of molecular sciences (2026). PMID: 42123472 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[46]
Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[47]
Zhou Y, Lei M, Lin Q et al.. “Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Diabetes technology & therapeutics (2026). PMID: 41640116 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification
[48]
Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[49]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[50]
Natale P, Green SC, Tunnicliffe DJ et al.. “Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.” The Cochrane database of systematic reviews (2025). PMID: 41263251 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[51]
Lin DS, Lee JK, Chen WJ. “Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33895840 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[52]
McGurnaghan SJ, Weir A, Bishop J et al.. “Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.” The lancet. Diabetes & endocrinology (2020). PMID: 33357491 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[53]
Kuppermann N, Ghetti S, Schunk JE et al.. “Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.” The New England journal of medicine (2018). PMID: 29897851 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[54]
Thomas M, Harjutsalo V, Feodoroff M et al.. “The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31529090 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[55]
Rosager EV, Heltø ALK, Fox Maule CU et al.. “Incidence and Characteristics of the Hyperosmolar Hyperglycemic State: A Danish Cohort Study.” Diabetes care (2024). PMID: 38085699 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[56]
Basu S, Zafra-Tanaka JH, Beran D. “Type 1 diabetes intervention clusters in resource-limited settings: a systematic review and economic evaluation.” The lancet. Diabetes & endocrinology (2026). PMID: 42140211 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[57]
Wu CY, Sharma A, Edwards JD et al.. “Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes.” Diabetologia (2025). PMID: 41204979 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[58]
Dhanasekaran M, Mohan S, Erickson D et al.. “Diabetic Ketoacidosis in Pregnancy: Clinical Risk Factors, Presentation, and Outcomes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35917830 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Endocrine Emergencies, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[59]
Fleming N, Hamblin PS, Story D et al.. “Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32302001 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[60]
Sooy M, Pyle L, Alonso GT et al.. “Lower Prevalence of Diabetic Ketoacidosis at Diagnosis in Research Participants Monitored for Hyperglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38470864 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[61]
Beck RW, Tamborlane WV, Bergenstal RM et al.. “The T1D Exchange clinic registry.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22996145 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[62]
Pasquel FJ, Umpierrez GE. “Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.” Diabetes care (2014). PMID: 25342831 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[63]
Khunti K, Del Prato S, Mathieu C et al.. “COVID-19, Hyperglycemia, and New-Onset Diabetes.” Diabetes care (2021). PMID: 34625431 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[64]
Bakhsh A, Saleemi A, Budhram D et al.. “Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes.” Diabetes care (2026). PMID: 41591367 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[65]
Gibbings NK, Kurdyak PA, Colton PA et al.. “Diabetic Ketoacidosis and Mortality in People With Type 1 Diabetes and Eating Disorders.” Diabetes care (2021). PMID: 34172488 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[66]
Polcwiartek C, Kragholm K, Rohde C et al.. “Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive population with schizophrenia: a nationwide nested case-control study.” Diabetologia (2017). PMID: 28593353 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[67]
Stephens JW, Dhatariya K, Beamish AJ et al.. “Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41840846 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[68]
Yoshida N, Goto H, Suzuki H et al.. “Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute.” European journal of endocrinology (2013). PMID: 23828957 ↗
L4REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[69]
Karges B, Rosenbauer J, Holterhus PM et al.. “Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes.” European journal of endocrinology (2015). PMID: 26088822 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[70]
Ehrmann D, Kulzer B, Roos T et al.. “Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes.” The lancet. Diabetes & endocrinology (2020). PMID: 32333879 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[71]
Apicella M, Campopiano MC, Mantuano M et al.. “COVID-19 in people with diabetes: understanding the reasons for worse outcomes.” The lancet. Diabetes & endocrinology (2020). PMID: 32687793 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[72]
Karges B, Rosenbauer J, Stahl-Pehe A et al.. “Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study.” The lancet. Diabetes & endocrinology (2024). PMID: 39701114 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[73]
Ward ZJ, Yeh JM, Reddy CL et al.. “Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis.” The lancet. Diabetes & endocrinology (2022). PMID: 36372070 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[74]
Sweety S, Panda S, Das RR. “Balanced electrolyte solution vs isotonic saline in the resuscitation of children with diabetic ketoacidosis: A randomized controlled trial.” World journal of clinical pediatrics (2026). PMID: 41884024 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Fertility
[75]
Khunti K, Valabhji J, Misra S. “Diabetes and the COVID-19 pandemic.” Diabetologia (2022). PMID: 36418578 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[76]
Martinenghi S, Merolla A, Grogan P et al.. “Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy.” Diabetologia (2025). PMID: 40439773 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[77]
Zhang T, Zhang H, Huang S et al.. “Worldwide prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes: A systematic review and meta-analysis.” Preventive medicine (2026). PMID: 42303108 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[78]
Carlsson A, Shepherd M, Ellard S et al.. “Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.” Diabetes care (2019). PMID: 31704690 ↗
L2COHORTCited in: Clinical Presentation
[79]
Cameron FJ, Scratch SE, Nadebaum C et al.. “Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.” Diabetes care (2014). PMID: 24855156 ↗
L2COHORTCited in: Clinical Presentation
[80]
Eliades M, El-Maouche D, Choudhary C et al.. “Takotsubo cardiomyopathy associated with thyrotoxicosis: a case report and review of the literature.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23560557 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[81]
Oak S, Gaur LK, Radtke J et al.. “Masked and overt autoantibodies specific to the DPD epitope of 65-kDa glutamate decarboxylase (GAD65-DPD) are associated with preserved β-cell functional reserve in ketosis-prone diabetes.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24601691 ↗
L2OTHERCited in: Clinical Presentation
[82]
Karakus KE, Fleury T, Baschal EE et al.. “Clinical Features and HLA Genetics Differ in Children at Type 1 Diabetes Onset by Hispanic Ethnicity.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39231249 ↗
L3OTHERCited in: Clinical Presentation
[83]
Wu L, Carlino MS, Brown DA et al.. “Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37997380 ↗
L4OTHERCited in: Clinical Presentation
[84]
Suzuki S, Makita Y, Mukai T et al.. “Molecular basis of neonatal diabetes in Japanese patients.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17635943 ↗
L4OTHERCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[85]
Denson AM, Rodriguez KE, Letourneau-Freiberg LR et al.. “Children With Pancreatic Hypoplasia Experience Poor Weight Gain and Labile Diabetes but Low Incidence of DKA.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41006196 ↗
L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment
[86]
Byun DJ, Braunstein R, Flynn J et al.. “Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.” Diabetes care (2020). PMID: 33051330 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[87]
Sasidharan Pillai S, Has P, Quintos JB et al.. “Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic.” Diabetes care (2023). PMID: 36637859 ↗
L3OTHERCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[88]
Hummel S, Carl J, Friedl N et al.. “Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation.” Diabetologia (2023). PMID: 37329450 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
[89]
Perry RJ, Petersen KF, Shulman GI. “Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis.” Diabetologia (2016). PMID: 26961503 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[90]
Katte JC, Bavuma C, Wild SH et al.. “Atypical diabetes subtypes in Black African populations.” Diabetologia (2026). PMID: 41770244 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[91]
Haddad N, Farhat N, Gravel CA et al.. “Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.” Journal of clinical medicine (2026). PMID: 42074909 ↗
L4SR_OBSCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[92]
Alsulaimi NMA. “Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: a case report and call for practice guidelines.” AME case reports (2026). PMID: 41676203 ↗
L4GUIDELINECited in: Clinical Presentation
[93]
Casalini E, Puliti D, Piccini B et al.. “Natural history of a pediatric cohort with islet autoantibody positivity: a single-center retrospective cohort study.” Journal of the Endocrine Society (2026). PMID: 42063580 ↗
L3COHORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[94]
Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗
L3COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[95]
Itagaki H, Endo T. “Acute esophageal necrosis in patients with diabetic ketoacidosis: a systematic review of clinical features and outcomes.” Clinical journal of gastroenterology (2026). PMID: 42406282 ↗
L4SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[96]
Ngo EMT, Rowe JM, Chillon TS et al.. “Type B insulin resistance with glycemic extremes: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42255432 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[97]
He M, Zheng Z, Guo X et al.. “Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event-two case reports and a literature review.” Frontiers in immunology (2026). PMID: 42183192 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
[98]
Choudhary P, Kolassa R, Keuthage W et al.. “Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.” The lancet. Diabetes & endocrinology (2022). PMID: 36058207 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[99]
Wilmot EG, Beltrand J, Guerci B et al.. “Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.” The lancet. Diabetes & endocrinology (2026). PMID: 41747751 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[100]
Beck RW, Riddlesworth TD, Ruedy KJ et al.. “Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28711468 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[101]
Wadwa RP, Reed ZW, Buckingham BA et al.. “Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 36920756 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[102]
Russell SJ, Beck RW, Damiano ER et al.. “Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36170500 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[103]
Boughton CK, Allen JM, Ware J et al.. “Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069870 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[104]
Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
[105]
Tauschmann M, Thabit H, Bally L et al.. “Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.” Lancet (London, England) (2018). PMID: 30292578 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
[106]
Kim JY, Kim S, Kim JH. “Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.” Diabetologia (2026). PMID: 41865177 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[107]
Gleeson H, Amin R, Maghnie M. “'Do no harm': management of craniopharyngioma.” European journal of endocrinology (2008). PMID: 18775978 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[108]
Prahalad P, Zaharieva D, Maahs DM. “Diabetes technology: an update.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41973910 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[109]
Palermo NE, Sadhu AR, McDonnell ME. “Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32556147 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[110]
Cao S, Cao S. “Hyperglycemic Hypernatremic Hypertonic State: A Predominant HHS Subtype and Its Clinical and Diagnostic Features.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40690721 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[111]
Lahoti A, Haque MR, Bianco ME et al.. “Trends of Diabetes in Youth (TrenDY) During COVID-19 Across the United States.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40658807 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[112]
Wright JJ, Johnson DB. “Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36481794 ↗
L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[113]
Okada A, Yamana H, Morita K et al.. “Potassium Concentration in Initial Fluid Therapy and In-Hospital Mortality of Patients with Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33493293 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[114]
Shi Y, Shen M, Zheng X et al.. “ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32905579 ↗
L4REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[115]
Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[116]
Phillip M, Achenbach P, Addala A et al.. “Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes.” Diabetes care (2024). PMID: 38912694 ↗
L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[117]
Holt RIG, DeVries JH, Hess-Fischl A et al.. “The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetes care (2021). PMID: 34593612 ↗
L1REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[118]
Hedlund E, Maziarz M, Lindahl T et al.. “Clinical Characteristics in Swedish Children With and Without Autoantibodies at the Time of Type 1 Diabetes Diagnosis.” Diabetes care (2025). PMID: 41091947 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[119]
Kilpatrick ES, Butler AE, Ostlundh L et al.. “Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis.” Diabetes care (2022). PMID: 35050366 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[120]
Alonso GT, Coakley A, Pyle L et al.. “Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010-2017.” Diabetes care (2019). PMID: 31601639 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
[121]
Dovc K, Neuman V, Gita G et al.. “Association of Diabetic Ketoacidosis at Onset, Diabetes Technology Uptake, and Clinical Outcomes After 1 and 2 Years of Follow-up: A Collaborative Analysis of Pediatric Registries Involving 9,269 Children With Type 1 Diabetes From Nine Countries.” Diabetes care (2025). PMID: 39965057 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
[122]
Hekkala A, Ilonen J, Knip M et al.. “Family history of diabetes and distribution of class II HLA genotypes in children with newly diagnosed type 1 diabetes: effect on diabetic ketoacidosis.” European journal of endocrinology (2011). PMID: 21890652 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment
[123]
Marigliano M, Morandi A, Maschio M et al.. “Diabetic ketoacidosis at diagnosis: role of family history and class II HLA genotypes.” European journal of endocrinology (2012). PMID: 23065995 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment
[124]
Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[125]
Thomas NJ, Jones SE, Weedon MN et al.. “Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.” The lancet. Diabetes & endocrinology (2017). PMID: 29199115 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[126]
Karges B, Tittel SR, Bey A et al.. “Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study.” The lancet. Diabetes & endocrinology (2023). PMID: 37004710 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[127]
Birkebaek NH, Kamrath C, Grimsmann JM et al.. “Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries.” The lancet. Diabetes & endocrinology (2022). PMID: 36202118 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
[128]
Sun Q, Zhao G. “The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42221148 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[129]
Ziegler AG, Cengiz E, Kay TWH. “The future of type 1 diabetes therapy.” Lancet (London, England) (2025). PMID: 40983070 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[130]
Holt RIG, DeVries JH, Hess-Fischl A et al.. “The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia (2021). PMID: 34590174 ↗
L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[131]
Phillip M, Achenbach P, Addala A et al.. “Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.” Diabetologia (2024). PMID: 38910151 ↗
L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[132]
Marcovecchio ML, Hendriks AEJ, Delfin C et al.. “The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.” Diabetologia (2024). PMID: 38517484 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[133]
He L, Chen L, Liu C. “Rapid-onset respiratory failure caused by diabetic ketoacidosis complicated with pulmonary mucormycosis: a case report and literature review.” Frontiers in medicine (2026). PMID: 42232973 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[134]
Xiao Q, Zhao Y, Du J et al.. “Oral myiasis complicating endotracheal intubation in a diabetic patient: a case report.” Frontiers in endocrinology (2026). PMID: 42222065 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[135]
Bhat SZ, Wu J, Perin J et al.. “Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39418352 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[136]
Pasquel FJ, Tsegka K, Wang H et al.. “Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study.” Diabetes care (2019). PMID: 31704689 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[137]
Hartmann-Boyce J, Highton P, Rees K et al.. “The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review.” The lancet. Diabetes & endocrinology (2024). PMID: 38272607 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[138]
Yousif MF, Dolak KD, Adhikari S et al.. “A Nested Case-Control Study of Adverse Outcomes in Children With Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39657257 ↗
L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[139]
Yousif MF, Dolak KD, Adhikari S et al.. “Risk Factors for Adverse Outcomes in Children With Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39031569 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[140]
Everett EM, Copeland TP, Moin T et al.. “Insulin Pump-related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35196382 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Special Populations, Pregnancy and Fertility
[141]
Rabbone I, Schiaffini R, Cherubini V et al.. “Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children?” Diabetes care (2020). PMID: 32778554 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[142]
Aye T, Mazaika PK, Mauras N et al.. “Impact of Early Diabetic Ketoacidosis on the Developing Brain.” Diabetes care (2018). PMID: 30573652 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[143]
Edge JA, Jakes RW, Roy Y et al.. “The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children.” Diabetologia (2006). PMID: 16847700 ↗
L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification
[144]
Li Y, Chen J, Gao Y et al.. “Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 41678006 ↗
L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
[145]
Gilbert BW, Turpin BB, Murray DS et al.. “The Evaluation of Early Basal Insulin in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41865288 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification
[146]
Sebastian-Valles F, Sampedro-Nuñez MA, Arranz-Martin JA et al.. “Pre- and in-hospital lactate ratio as a predictor of mortality in severe diabetic ketoacidosis: a multicenter prospective cohort study.” European journal of internal medicine (2026). PMID: 41521082 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification
[147]
Wang Z, Zhang Y, Yang H et al.. “Prevalence and prognostic impact of rhabdomyolysis in adults hospitalized with diabetic ketosis: a 10-year single-center cohort study.” Endocrine connections (2026). PMID: 41670427 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification
[148]
Rosenstock J, Marquard J, Laffel LM et al.. “Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.” Diabetes care (2018). PMID: 30287422 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[149]
Tamborlane WV, Laffel LM, Shehadeh N et al.. “Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.” The lancet. Diabetes & endocrinology (2022). PMID: 35378069 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[150]
von Herrath M, Bain SC, Bode B et al.. “Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.” The lancet. Diabetes & endocrinology (2021). PMID: 33662334 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[151]
Battelino T, Kuusela S, Shetty A et al.. “Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial.” The lancet. Diabetes & endocrinology (2025). PMID: 40544853 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[152]
Wiviott SD, Raz I, Bonaca MP et al.. “Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2018). PMID: 30415602 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[153]
Bhatt DL, Szarek M, Pitt B et al.. “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 33200891 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[154]
Brown SA, Kovatchev BP, Raghinaru D et al.. “Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.” The New England journal of medicine (2019). PMID: 31618560 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[155]
Burnside MJ, Lewis DM, Crocket HR et al.. “Open-Source Automated Insulin Delivery in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069869 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[156]
Elbarbary NS, Ismail EA, El-Hamamsy MH et al.. “The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.” Diabetologia (2024). PMID: 39271520 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[157]
Taylor SI, Blau JE, Rother KI. “SGLT2 Inhibitors May Predispose to Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26086329 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies
[158]
Leichter SB, Felton JL, Geno Rasmussen C et al.. “Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40171881 ↗
L5OTHERCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[159]
Wang Y, Guo H, Wang G et al.. “COVID-19 as a Trigger for Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36950864 ↗
L5OTHERCited in: Acute Management and Endocrine Emergencies
[160]
Tian Y, Qiu Z, Wang F et al.. “Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in China: A National Study.” Diabetes care (2024). PMID: 39255435 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[161]
Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[162]
Lei M, Lin Q, Zhou Y et al.. “Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 42410321 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies
[163]
Dhatariya K, Bergenstal RM, Al-Sofiani M et al.. “Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology.” The lancet. Diabetes & endocrinology (2026). PMID: 41381175 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[164]
Zimmermann AT, Lanzinger S, Kummernes SJ et al.. “Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries.” The lancet. Diabetes & endocrinology (2024). PMID: 39622257 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[165]
Sabelli N, Pasqua MR, Perz N et al.. “Transient Benign Ketosis Is Common in Type 1 Diabetes During Very-Low Carbohydrate States: Novel Data from Continuous Ketone Sensor.” Diabetes technology & therapeutics (2026). PMID: 42381172 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[166]
Cameron FJ, Wherrett DK. “Care of diabetes in children and adolescents: controversies, changes, and consensus.” Lancet (London, England) (2015). PMID: 26009230 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[167]
Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
[168]
Fawaz L, Badawi N, Hasan M et al.. “Impact of telemonitoring on glycemic control and quality of life in pediatric patients with type 1 diabetes, single center interventional control study.” BMC pediatrics (2026). PMID: 42332616 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[169]
Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N et al.. “Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.” The Cochrane database of systematic reviews (2016). PMID: 26798030 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[170]
Lo C, Toyama T, Wang Y et al.. “Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.” The Cochrane database of systematic reviews (2018). PMID: 30246878 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[171]
Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[172]
Kim M, Park E. “Continuous Glucose Monitoring and Hypoglycaemia Risk During Paediatric DKA Treatment in the PICU: A Retrospective Cohort Study.” Diabetes, obesity & metabolism (2026). PMID: 42421174 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[173]
Lim CE, Pasternak B, Eliasson B et al.. “Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.” The Lancet regional health. Europe (2026). PMID: 42306189 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[174]
Bao Z, Hu J, Sun Y et al.. “Renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged ≥ 65 years with non-dialysis chronic kidney disease: a systematic review and meta-analysis of subgroup-level estimates derived from randomized trials.” BMC cardiovascular disorders (2026). PMID: 42420866 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[175]
Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗
L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[176]
Donovan LE, Feig DS, Lemieux P et al.. “A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes.” Diabetes care (2023). PMID: 37824779 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[177]
Groop PH, Dandona P, Phillip M et al.. “Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.” The lancet. Diabetes & endocrinology (2020). PMID: 32946821 ↗
L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[178]
Bosi E, Choudhary P, de Valk HW et al.. “Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.” The lancet. Diabetes & endocrinology (2019). PMID: 31047902 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[179]
Dandona P, Mathieu C, Phillip M et al.. “Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28919061 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[180]
Garg SK, Henry RR, Banks P et al.. “Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.” The New England journal of medicine (2017). PMID: 28899222 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[181]
Gübeli A, Steiner N, Limacher A et al.. “Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial.” Diabetologia (2025). PMID: 40629004 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[182]
Peters AL, Buschur EO, Buse JB et al.. “Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.” Diabetes care (2015). PMID: 26078479 ↗
L4OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[183]
AbuJlambo A, AbuZarifa M, Sawh RRR et al.. “Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta-Analysis.” Endocrinology, diabetes & metabolism (2026). PMID: 42405473 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[184]
Mata E, Resende B, Castro M et al.. “Efficacy and Safety of Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis.” Korean circulation journal (2026). PMID: 42204740 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[185]
Fisher JN, Kitabchi AE. “A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis.” The Journal of clinical endocrinology and metabolism (1983). PMID: 6406531 ↗
L1RCTCited in: History and Evolution of Treatment
[186]
Anderson JJA, Couper JJ, Giles LC et al.. “Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 29040598 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[187]
Ho J, Nicolucci AC, Virtanen H et al.. “Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31188437 ↗
L1RCTCited in: History and Evolution of Treatment
[188]
Hsia E, Seggelke S, Gibbs J et al.. “Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22685233 ↗
L1RCTCited in: History and Evolution of Treatment
[189]
Kuhadiya ND, Ghanim H, Mehta A et al.. “Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27490915 ↗
L1RCTCited in: History and Evolution of Treatment
[190]
Sherwood JS, Castellanos LE, O'Connor MY et al.. “Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes.” Diabetes care (2024). PMID: 37874987 ↗
L1RCTCited in: History and Evolution of Treatment
[191]
Ghetti S, Kuppermann N, Rewers A et al.. “Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes.” Diabetes care (2020). PMID: 32962981 ↗
L2RCTCited in: History and Evolution of Treatment
[192]
Beunen K, Gillard P, Van Wilder N et al.. “Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.” Diabetes care (2024). PMID: 39331059 ↗
L2RCTCited in: History and Evolution of Treatment
[193]
McAuley SA, Trawley S, Vogrin S et al.. “Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.” Diabetes care (2022). PMID: 34844995 ↗
L1RCTCited in: History and Evolution of Treatment
[194]
Pasqua MR, Jafar A, Kobayati A et al.. “Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.” Diabetes care (2023). PMID: 36331522 ↗
L1RCTCited in: History and Evolution of Treatment
[195]
. “Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience.” Diabetes care (2013). PMID: 23704676 ↗
L1RCTCited in: History and Evolution of Treatment
[196]
Breton MD, Kanapka LG, Beck RW et al.. “A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.” The New England journal of medicine (2020). PMID: 32846062 ↗
L1RCTCited in: History and Evolution of Treatment
[197]
Fisher JN, Shahshahani MN, Kitabchi AE. “Diabetic ketoacidosis: low-dose insulin therapy by various routes.” The New England journal of medicine (1977). PMID: 406561 ↗
L1RCTCited in: History and Evolution of Treatment
[198]
Kim JY, Jin SM, Kang ES et al.. “Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.” Diabetologia (2024). PMID: 38634887 ↗
L1RCTCited in: History and Evolution of Treatment
[199]
Voss TS, Vendelbo MH, Kampmann U et al.. “Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.” Diabetologia (2018). PMID: 30506451 ↗
L1RCTCited in: History and Evolution of Treatment
[200]
Oskarsson P, Antuna R, Geelhoed-Duijvestijn P et al.. “Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.” Diabetologia (2017). PMID: 29273897 ↗
L2RCTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[201]
Svart MV, Rittig N, Kampmann U et al.. “Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.” Diabetologia (2017). PMID: 28389705 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
[202]
Akturk HK, Alkanani A, Zhao Z et al.. “PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30124874 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment, Complications and Long-term Sequelae
[203]
Valerio D. “Acute diabetic abdomen in childhood.” Lancet (London, England) (1976). PMID: 54584 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[204]
Huang Z, Wu Y, Tang C et al.. “A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia.” Diabetes, obesity & metabolism (2026). PMID: 41853855 ↗
L1RCTCited in: History and Evolution of Treatment
[205]
Baek G, Lee E. “Effectiveness of a virtual reality simulation based on experiential learning theory for enhancing diabetic ketoacidosis management competencies: a randomized controlled trial.” BMC medical education (2026). PMID: 41814271 ↗
L1RCTCited in: History and Evolution of Treatment
[206]
Jendle JH, Garg SK, Thivolet C et al.. “Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.” Frontiers in endocrinology (2025). PMID: 41488135 ↗
L1RCTCited in: History and Evolution of Treatment
[207]
Lundbaek K, Hansen AP, Orskov H et al.. “Failure of somatostatin to correct manifest diabetic ketoacidosis.” Lancet (London, England) (1976). PMID: 55530 ↗
L4OTHERCited in: History and Evolution of Treatment
[208]
Liu Y, Wang Y, Wu W et al.. “Glycaemic Outcomes of a Novel Model-Predictive-Control-Based Hybrid Closed-Loop System in Chinese Adolescents and Adults With Type 1 Diabetes: A Multicentre Pivotal Trial.” Diabetes, obesity & metabolism (2026). PMID: 41913542 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[209]
Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[210]
Nimri R, Rachmiel M, Yackobovitch-Gavan M et al.. “Symptoms and Glycemic Control in Young People With Type 1 Diabetes Following SARS-CoV-2 Infection: An Observational Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35524727 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[211]
Chao LC, Vidmar AP, Georgia S. “Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic.” Diabetes care (2021). PMID: 33905347 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[212]
Keiner ES, Slaughter JC, Datye KA et al.. “COVID-19 Exacerbates Insulin Resistance During Diabetic Ketoacidosis in Pediatric Patients With Type 1 Diabetes.” Diabetes care (2022). PMID: 35944264 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[213]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[214]
Briones-Claudett KH, Benites-Solis J, Delgado-Cedeño P et al.. “Case Report: High-altitude exposure and severe respiratory infection precipitating diabetic ketoacidosis: new-onset ketosis-prone diabetes unmasked by physiological stress.” Frontiers in medicine (2026). PMID: 41836962 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[215]
Wu Y, Deng H, Sun J et al.. “Case Report: Diabetic ketoacidosis in a patient with Klinefelter syndrome: a rare and complex presentation.” Frontiers in endocrinology (2026). PMID: 41613957 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[216]
Zhang K, Wang Y, Chen S et al.. “Cohen syndrome with novel VPS13B variants presenting as early-onset diabetes: a case report.” Acta diabetologica (2026). PMID: 41591480 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[217]
Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[218]
Lin CH, Yeh NC, Wang JJ et al.. “Effect of Chronic Pancreatitis on Complications and Mortality in DM Patients: A 10-year Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31974550 ↗
L2COHORTCited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[219]
Haddad N, Farhat N, Gravel CA et al.. “Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies.” Journal of clinical medicine (2026). PMID: 42123269 ↗
L2SR_OBSCited in: Complications and Long-term Sequelae
[220]
Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗
L2SR_OBSCited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[221]
Li L, Shen S, Ouyang J et al.. “Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22419704 ↗
L4TRIAL_NONRANDOMCited in: Prognosis, Natural History and Prevention
[222]
Dunne JL, Koralova A, Sutphin J et al.. “Parent and Pediatrician Preferences for Type 1 Diabetes Screening in the U.S.” Diabetes care (2020). PMID: 33303637 ↗
L5OTHERCited in: Prognosis, Natural History and Prevention
[223]
McQueen RB, Geno Rasmussen C, Waugh K et al.. “Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado.” Diabetes care (2020). PMID: 32327420 ↗
L2OTHERCited in: Prognosis, Natural History and Prevention
[224]
Bapat P, Budhram DR, Bakhsh A et al.. “Longitudinal Determination of Diabetes Complications and Other Clinical Variables as Risk Factors for Diabetic Ketoacidosis in Type 1 Diabetes.” Diabetes care (2025). PMID: 39950992 ↗
L2OTHERCited in: Prognosis, Natural History and Prevention
[225]
Wang CA, Wang WJ, Chen JY et al.. “Impact of sodium-glucose cotransporter-2 inhibitors on clinical outcomes in patients with type 1 diabetes after dialysis-requiring acute kidney injury: a real-world cohort study.” Diabetes research and clinical practice (2026). PMID: 42049097 ↗
L2COHORTCited in: Prognosis, Natural History and Prevention
[226]
Chia JE, Ang SP, Wu S et al.. “Age and sex differences in diabetic ketoacidosis outcomes in type 1 diabetes: a national cohort study.” BMJ open diabetes research & care (2026). PMID: 41698751 ↗
L2COHORTCited in: Prognosis, Natural History and Prevention
[227]
Bongaerts B, Leuwer A, Sadiq F et al.. “Models of care for children and adolescents with type 1 diabetes in low- and middle-income countries: a scoping review.” The Cochrane database of systematic reviews (2025). PMID: 40927968 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[228]
Cahn A, Mosenzon O, Wiviott SD et al.. “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.” Diabetes care (2019). PMID: 31843945 ↗
L1RCTCited in: Special Populations, Pregnancy and Fertility
[229]
Oktavian P, Kencono Wungu CD, Amin IM et al.. “Automated Insulin Delivery in Young Children with Type 1 Diabetes: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41877382 ↗
L2SR_OBSCited in: Special Populations, Pregnancy and Fertility
[230]
Everett EM, Copeland TP, Moin T et al.. “National Trends in Pediatric Admissions for Diabetic Ketoacidosis, 2006-2016.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33942077 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[231]
Parikh HM, Remedios CL, Hampe CS et al.. “Data Mining Framework for Discovering and Clustering Phenotypes of Atypical Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36314086 ↗
L5OTHERCited in: Special Populations, Pregnancy and Fertility
[232]
Donovan LE, Lemieux P, Yamamoto JM et al.. “Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.” Diabetes care (2026). PMID: 42201836 ↗
L1RCTCited in: Special Populations, Pregnancy and Fertility
[233]
Maahs DM, Hermann JM, DuBose SN et al.. “Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries.” Diabetologia (2014). PMID: 24893863 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[234]
Matejko B, Cyranka K, Suduł P et al.. “Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study.” Diabetologia (2026). PMID: 42347980 ↗
L1OTHERCited in: Special Populations, Pregnancy and Fertility
[235]
Kallas-Koeman MM, Kong JM, Klinke JA et al.. “Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes.” Diabetologia (2014). PMID: 24434960 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[236]
Turtinen M, Härkönen T, Parkkola A et al.. “Characteristics of familial type 1 diabetes: effects of the relationship to the affected family member on phenotype and genotype at diagnosis.” Diabetologia (2019). PMID: 31346657 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[237]
Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

Synonyms and Abbreviations

Key Diagnostic Terms

Classification of DKA Variants

Clinical Significance

Axis Physiology, Pathophysiology and Biochemical Signature

Biochemical Signature

Special Pathophysiologic Mechanisms

Epidemiology, Etiology and Risk Factors

Demographic Patterns

Temporal Trends

Risk Factors

Special Considerations

Clinical Presentation

Presenting Symptoms

Neurological Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis and Laboratory Confirmation

Gold-Standard Diagnostic Criteria

Laboratory Studies

Imaging

Diagnostic Algorithm

Differential Diagnosis

Severity, Staging and Risk Stratification

Severity Classification

Risk Stratification for Adverse Outcomes

Prognostic Biomarkers

Acute Management and Endocrine Emergencies

Step 1: Fluid Resuscitation

Step 2: Insulin Therapy

Step 3: Potassium Replacement

Step 4: Bicarbonate, Use Only in Extreme Acidosis

Step 5: Monitoring and Titration

Step 6: Resolution and Transition to Subcutaneous Insulin

What NOT to Do

Controversies and Guideline Disagreement

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

Insulin Replacement: Technology-Enabled Treat-to-Target

Suppression: Adjunctive Pharmacotherapy

Definitive Therapies: Transplantation and Immunomodulation

Prevention Through Screening and Education

Controversies and Guideline Disagreement

History and Evolution of Treatment

Controversies and Guideline Disagreement

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

Autoimmune Polyendocrine Syndromes

Monogenic and Syndromic Diabetes

Co-Axis Endocrine Effects

COVID-19 as a Co-Axis Perturbation

Complications and Long-term Sequelae

Acute Complications of DKA Therapy

Long-term Sequelae and Recurrence

Prevention Strategies

Prognosis, Natural History and Prevention

Prevention Strategies

Screening and Early Detection

Special Populations, Pregnancy and Fertility

Pediatrics

Pregnancy

Elderly

Immunocompromised

References

as a Co-Axis Perturbation